

Michael Berk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5054974/publications.pdf>

Version: 2024-02-01

1,285
papers

80,928
citations

630

127
h-index

1410

227
g-index

1368
all docs

1368
docs citations

1368
times ranked

73291
citing authors

#	ARTICLE	IF	CITATIONS
1	Nutrition and bipolar disorder: a systematic review. <i>Nutritional Neuroscience</i> , 2023, 26, 637-651.	1.5	12
2	In vivo hippocampal subfield volumes in bipolar disorder: A mega-analysis from The Enhancing Neuro Imaging Genetics through Meta-Analysis Bipolar Disorder Working Group. <i>Human Brain Mapping</i> , 2022, 43, 385-398.	1.9	41
3	Intracranial and subcortical volumes in adolescents with early-onset psychosis: A multisite mega-analysis from the ENIGMA consortium. <i>Human Brain Mapping</i> , 2022, 43, 373-384.	1.9	27
4	What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from the ENIGMA Bipolar Disorder Working Group. <i>Human Brain Mapping</i> , 2022, 43, 56-82.	1.9	67
5	Personality disorder among youth with first episode psychotic mania: An important target for specific treatment?. <i>Microbial Biotechnology</i> , 2022, 16, 256-263.	0.9	1
6	Confirmatory evaluation of the bipolar depression rating scale (BDRS) in a large sample of female patients with bipolar depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 85-91.	1.2	0
7	Disruption of circadian rhythm and risk of autism spectrum disorder: role of immune-inflammatory, oxidative stress, metabolic and neurotransmitter pathways. <i>Reviews in the Neurosciences</i> , 2022, 33, 93-109.	1.4	11
8	Biomarkers for Deep Brain Stimulation in Animal Models of Depression. <i>Neuromodulation</i> , 2022, 25, 161-170.	0.4	5
9	Cognition-immune interactions between executive function and working memory, tumour necrosis factor-alpha (TNF-alpha) and soluble TNF receptors (sTNFR1 and sTNFR2) in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 67-77.	1.3	11
10	Social isolation, social support and loneliness as independent concepts, and their relationship with health-related quality of life among older women. <i>Aging and Mental Health</i> , 2022, 26, 1335-1344.	1.5	36
11	Cognitive Profile and Relationship with Quality of Life and Psychosocial Functioning in Mood Disorders. <i>Archives of Clinical Neuropsychology</i> , 2022, 37, 376-389.	0.3	4
12	Lithium therapy and weight change in people with bipolar disorder: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 134, 104266.	2.9	19
13	Diabetes and mood disorders: shared mechanisms and therapeutic opportunities. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 183-195.	1.2	10
14	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. <i>CNS Spectrums</i> , 2022, 27, 716-723.	0.7	3
15	A protocol for the first episode psychosis outcome study (FEPOS): a 15-year follow-up after treatment at the Early Psychosis Prevention and Intervention Centre, Melbourne, Australia. <i>Microbial Biotechnology</i> , 2022, 16, 715-723.	0.9	3
16	Longitudinal Structural Brain Changes in Bipolar Disorder: A Multicenter Neuroimaging Study of 1232 Individuals by the ENIGMA Bipolar Disorder Working Group. <i>Biological Psychiatry</i> , 2022, 91, 582-592.	0.7	29
17	The influence of childhood trauma on the treatment outcomes of pharmacological and/or psychological interventions for adolescents and adults with bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 296, 350-362.	2.0	9
18	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	2.0	33

#	ARTICLE	IF	CITATIONS
19	Inflammation and depression in young people: a systematic review and proposed inflammatory pathways. <i>Molecular Psychiatry</i> , 2022, 27, 315-327.	4.1	35
20	Results of the COVID-19 mental health international for the general population (COMET-G) study. <i>European Neuropsychopharmacology</i> , 2022, 54, 21-40.	0.3	84
21	The Australian Genetics of Depression Study: New Risk Loci and Dissecting Heterogeneity Between Subtypes. <i>Biological Psychiatry</i> , 2022, 92, 227-235.	0.7	18
22	What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines. <i>Journal of Affective Disorders</i> , 2022, 298, 565-576.	2.0	8
23	Does metabolic syndrome or its component factors alter the course of bipolar disorder? A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 142-153.	2.9	26
24	The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 289-303.	2.9	24
25	Editorial: A fresh look at mood and anxiety disorders: recent developments and emerging concepts. <i>Current Opinion in Psychiatry</i> , 2022, 35, 1-2.	3.1	0
26	Intertwined associations between oxidative and nitrosative stress and endocannabinoid system pathways: Relevance for neuropsychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110481.	2.5	6
27	Attentional engagement and inhibitory control according to positive and negative symptoms in schizophrenia: An emotional antisaccade task. <i>Schizophrenia Research</i> , 2022, 239, 142-150.	1.1	3
28	The specific phenotype of depression in recent onset schizophrenia spectrum disorders: A symptom profile and network comparison to recent onset major depressive disorder without psychotic features. <i>Schizophrenia Research</i> , 2022, 240, 52-60.	1.1	1
29	Cocaine increases stimulation-evoked serotonin efflux in the nucleus accumbens. <i>Journal of Neurophysiology</i> , 2022, 127, 714-724.	0.9	9
30	Effect of Glucocorticoid and 11 β -Hydroxysteroid-Dehydrogenase Type 1 (11 β -HSD1) in Neurological and Psychiatric Disorders. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 387-398.	1.0	4
31	Supporting Dietary Change for the Treatment of Mood Disorders in Adults: How Can We Harness Digital Platforms?. <i>Psychiatric Annals</i> , 2022, 52, 62-66.	0.1	0
32	A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. <i>Molecular Psychiatry</i> , 2022, 27, 1920-1935.	4.1	164
33	A systematic review and meta-analysis of structural and functional brain alterations in individuals with genetic and clinical high-risk for psychosis and bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 117, 110540.	2.5	20
34	N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 117, 110550.	2.5	5
35	Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 615-627.	2.2	9
36	Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative. <i>Bipolar Disorders</i> , 2022, 24, 709-719.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia. <i>Molecular Neurobiology</i> , 2022, 59, 3485-3503.	1.9	19
38	Strategies and foundations for scientific discovery in longitudinal studies of bipolar disorder. <i>Bipolar Disorders</i> , 2022, 24, 499-508.	1.1	15
39	The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders. <i>CNS Drugs</i> , 2022, 36, 451-482.	2.7	24
40	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 424-455.	1.3	49
41	Scientists Against War: A Plea to World Leaders for Better Governance. <i>Sleep and Vigilance</i> , 2022, 6, 1-6.	0.4	6
42	Attachment insecurity partially mediates the relationship between childhood trauma and depression severity in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 591-603.	2.2	9
43	Time for united action on depression: a Lancet World Psychiatric Association Commission. <i>Lancet</i> , 2022, 399, 957-1022.	6.3	292
44	Evaluating telehealth lifestyle therapy versus telehealth psychotherapy for reducing depression in adults with COVID-19 related distress: the curbing anxiety and depression using lifestyle medicine (CALM) randomised non-inferiority trial protocol. <i>BMC Psychiatry</i> , 2022, 22, 219.	1.1	3
45	Reviving academic psychiatry in Australia and New Zealand. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, , 000486742210919.	1.3	4
46	Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder. <i>Frontiers in Pharmacology</i> , 2022, 13, 873271.	1.6	7
47	What Injured Workers With Complex Claims Look For in Online Communities: Netnographic Analysis. <i>Journal of Medical Internet Research</i> , 2022, 24, e17180.	2.1	2
48	Bipolar disorder and bone health: A case-control study. <i>Journal of Affective Disorders</i> , 2022, 308, 39-43.	2.0	2
49	Common effects of bipolar disorder medications on expression quantitative trait loci genes. <i>Journal of Psychiatric Research</i> , 2022, 150, 105-112.	1.5	2
50	A pragmatic preference trial of therapeutic yoga as an adjunct to group cognitive behaviour therapy versus group CBT alone for depression and anxiety. <i>Journal of Affective Disorders</i> , 2022, 307, 1-10.	2.0	2
51	Early intervention comes late. <i>European Neuropsychopharmacology</i> , 2022, 59, 1-3.	0.3	6
52	Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression. <i>Acta Neuropsychiatrica</i> , 2022, 34, 220-227.	1.0	7
53	Deep Brain Stimulation for Addictive Disorders—Where Are We Now?. <i>Neurotherapeutics</i> , 2022, 19, 1193-1215.	2.1	10
54	Trajectories of depressive symptoms in older adults and associated health outcomes. <i>Nature Aging</i> , 2022, 2, 295-302.	5.3	7

#	ARTICLE	IF	CITATIONS
55	Mixed Methods Thematic Analysis of a Randomised Controlled Trial of Adjunctive Mitochondrial Agents for Bipolar Depression. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 300-310.	0.9	2
56	Hypoxia-Reoxygenation Couples 3Î²HSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer. <i>Cancer Research</i> , 2022, 82, 2417-2430.	0.4	4
57	H3K9 methylation drives resistance to androgen receptor antagonist therapy in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2114324119.	3.3	21
58	Investing in Late-Life Brain Capital. <i>Innovation in Aging</i> , 2022, 6, .	0.0	8
59	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. <i>European Neuropsychopharmacology</i> , 2022, 60, 91-99.	0.3	9
60	Effects of Psychotropic Drugs on Ribosomal Genes and Protein Synthesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7180.	1.8	8
61	Associations of Cardiovascular Agents and Metformin with Depression Symptoms: A Cross-Sectional Analysis from the HUNT Study, Norway. <i>Drugs - Real World Outcomes</i> , 2022, 9, 503-516.	0.7	4
62	Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7508.	1.8	2
63	The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: Data from the international COMET-G study.. <i>Psychiatry Research</i> , 2022, 315, 114702.	1.7	17
64	Brain derived neurotrophic factor in perioperative neurocognitive disorders: Current evidence and future directions. <i>Neurobiology of Learning and Memory</i> , 2022, 193, 107656.	1.0	6
65	The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. <i>Molecular Psychiatry</i> , 2021, 26, 4158-4178.	4.1	135
66	Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 784-798.	1.3	16
67	Measuring fatigue: a meta-review. <i>International Journal of Dermatology</i> , 2021, 60, 1053-1069.	0.5	26
68	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 483-494.	1.3	32
69	Clinical and demographic characteristics of people who smoke versus inject crystalline methamphetamine in Australia: Findings from a pharmacotherapy trial. <i>Drug and Alcohol Review</i> , 2021, 40, 1249-1255.	1.1	8
70	The effect of concomitant benzodiazepine use on neurocognition in stable, long-term patients with bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 1005-1016.	1.3	10
71	Effects of psychoactive drugs on cellular bioenergetic pathways. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 79-93.	1.3	5
72	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. <i>CNS Spectrums</i> , 2021, 26, 290-298.	0.7	5

#	ARTICLE	IF	CITATIONS
73	Systemic inflammation and grey matter volume in schizophrenia and bipolar disorder: Moderation by childhood trauma severity. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 105, 110013.	2.5	23
74	Diet and depression: exploring the biological mechanisms of action. <i>Molecular Psychiatry</i> , 2021, 26, 134-150.	4.1	265
75	Ultraprocessed food and chronic noncommunicable diseases: A systematic review and meta-analysis of 43 observational studies. <i>Obesity Reviews</i> , 2021, 22, e13146.	3.1	298
76	Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 537-541.	2.9	42
77	Does guideline-concordant care predict naturalistic outcomes in youth with early stage bipolar I disorder?. <i>Journal of Affective Disorders</i> , 2021, 278, 23-32.	2.0	2
78	The prevalence, odds and predictors of lifespan comorbid eating disorder among people with a primary diagnosis of bipolar disorders, and vice-versa: Systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2021, 280, 409-431.	2.0	28
79	The rebirth of lithium as the archetypal mood stabilizer. <i>Bipolar Disorders</i> , 2021, 23, 211-212.	1.1	6
80	Design of a brief psychological intervention for youth who self-harm: a formative study in India. <i>Evidence-Based Mental Health</i> , 2021, 24, e2-e2.	2.2	6
81	Genetics of methamphetamine use disorder: A systematic review and meta-analyses of gene association studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 48-74.	2.9	16
82	Cumulative Cardiovascular Disease Risk and Triglycerides Differentially Relate to Subdomains of Executive Function in Bipolar Disorder; preliminary findings. <i>Journal of Affective Disorders</i> , 2021, 278, 556-562.	2.0	10
83	Systematic review and meta-analysis of the role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders. <i>Journal of Affective Disorders</i> , 2021, 279, 711-721.	2.0	9
84	A novel way to quantify schizophrenia symptoms in clinical trials. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13398.	1.7	13
85	A Brain Capital Grand Strategy: toward economic reimagination. <i>Molecular Psychiatry</i> , 2021, 26, 3-22.	4.1	41
86	Preventing the development of severe COVID-19 by modifying immunothrombosis. <i>Life Sciences</i> , 2021, 264, 118617.	2.0	40
87	A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 262-273.	0.9	11
88	Psychosocial interventions for self-harm in low-income and middle-income countries: systematic review and theory of change. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 1729-1750.	1.6	13
89	Role of the T-Cell Network in Psychiatric Disorders. , 2021, , 109-132.		0
90	Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial. <i>Molecular Psychiatry</i> , 2021, 26, 5161-5170.	4.1	18

#	ARTICLE	IF	CITATIONS
91	Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d'essais randomisés contrôlés. Canadian Journal of Psychiatry, 2021, 66, 849-862.	0.9	19
92	Anticonvulsant use and bone health in a population-based study of men and women: cross-sectional data from the Geelong Osteoporosis Study. BMC Musculoskeletal Disorders, 2021, 22, 172.	0.8	9
93	The effects of childhood emotional maltreatment and alexithymia on depressive and manic symptoms and suicidal ideation in females with bipolar disorder: emotion dysregulation as a mediator. International Journal of Psychiatry in Clinical Practice, 2021, 25, 90-102.	1.2	10
94	Relationships Between Different Dimensions of Social Support and Suicidal Ideation in Young People with Major Depressive Disorder. Journal of Affective Disorders, 2021, 281, 714-720.	2.0	21
95	Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease: A Meta-Analysis of Mood Effects. Neuropsychology Review, 2021, 31, 385-401.	2.5	19
96	Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. Australian and New Zealand Journal of Psychiatry, 2021, 55, 1127-1133.	1.3	24
97	Psychometric Properties of the Chinese Version of the Bipolar Depression Rating Scale for Bipolar Disorder. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 787-795.	1.0	2
98	The evolution of clinical trials in response to COVID-19. Medical Journal of Australia, 2021, 214, 332.	0.8	4
99	Nutrition-based interventions for mood disorders. Expert Review of Neurotherapeutics, 2021, 21, 303-315.	1.4	25
100	The mental health and lifestyle impacts of COVID-19 on bipolar disorder. Journal of Affective Disorders, 2021, 282, 442-447.	2.0	33
101	The Added Burden of Personality Disorder on Subsidized Australian Health Service Utilization Among Women With Mental State Disorder. Frontiers in Global Women's Health, 2021, 2, 615057.	1.1	1
102	Optimizing Engagement in an Online Dietary Intervention for Depression (My Food & Mood Version) Tj ETQq0,0,0 rgBT /Qverlock 1	1.7	13
103	Major depressive disorders and bipolar disorders in older adults: Commentary on the RANZCP mood disorders guideline summaries. Bipolar Disorders, 2021, 23, 416-417.	1.1	0
104	Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people. Australian and New Zealand Journal of Psychiatry, 2021, 55, 506-516.	1.3	3
105	Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. Journal of Internal Medicine, 2021, 290, 621-631.	2.7	146
106	How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Revista Brasileira De Psiquiatria, 2021, 43, 189-202.	0.9	32
107	Influence of childhood trauma on the treatment outcomes of pharmacological and/or psychological interventions for adolescents and adults with bipolar disorder: protocol for a systematic review and meta-analysis. BMJ Open, 2021, 11, e044569.	0.8	1
108	Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression. Drugs and Aging, 2021, 38, 451-467.	1.3	9

#	ARTICLE	IF	CITATIONS
109	Prebiotic and probiotic supplementation and the tryptophan-kynurenine pathway: A systematic review and meta analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 123, 1-13.	2.9	39
110	Associations between dairy consumption and constipation in adults: A cross-sectional study. <i>Nutrition and Health</i> , 2021, , 026010602110047.	0.6	4
111	Assessing the feasibility of an m-Health intervention for changing diet quality and mood in individuals with depression: the My Food & Mood program. <i>International Review of Psychiatry</i> , 2021, 33, 266-279.	1.4	5
112	The Dietary Inflammatory Index and Human Health: An Umbrella Review of Meta-Analyses of Observational Studies. <i>Advances in Nutrition</i> , 2021, 12, 1681-1690.	2.9	95
113	Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	20
114	Building brain capital. <i>Neuron</i> , 2021, 109, 1430-1432.	3.8	5
115	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021, 178, 383-399.	4.0	270
116	A Review of the Global Impact of the COVID-19 Pandemic on Public Mental Health, with a Comparison Between the USA, Australia, and Poland with Taiwan and Thailand. <i>Medical Science Monitor</i> , 2021, 27, e932220.	0.5	9
117	Preventive psychiatry: a blueprint for improving the mental health of young people. <i>World Psychiatry</i> , 2021, 20, 200-221.	4.8	183
118	Treatment of Refractory Obsessive-Compulsive Disorder with Nutraceuticals (TRON): A 20-week, open label pilot study. <i>CNS Spectrums</i> , 2021, , 1-35.	0.7	4
119	Cognitive ability and metabolic physical health in first-episode psychosis. <i>Schizophrenia Research: Cognition</i> , 2021, 24, 100194.	0.7	5
120	Miniature FSCV Devices: A Review. <i>IEEE Sensors Journal</i> , 2021, 21, 13006-13018.	2.4	2
121	The role of high-density lipoprotein cholesterol, apolipoprotein A and paraoxonase-1 in the pathophysiology of neuroprogressive disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 125, 244-263.	2.9	29
122	The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2021, 12, 626486.	1.3	3
123	Mood Regulatory Actions of Active and Sham Nucleus Accumbens Deep Brain Stimulation in Antidepressant Resistant Rats. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 644921.	1.0	4
124	Brain Health Living Labs. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 698-703.	0.6	3
125	Not in education, employment and training status in the early stages of bipolar I disorder with psychotic features. <i>Microbial Biotechnology</i> , 2021, , .	0.9	1
126	The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment. <i>Frontiers in Psychiatry</i> , 2021, 12, 546801.	1.3	61

#	ARTICLE	IF	CITATIONS
127	Cocaine-Induced Changes in Tonic Dopamine Concentrations Measured Using Multiple-Cyclic Square Wave Voltammetry in vivo. <i>Frontiers in Pharmacology</i> , 2021, 12, 705254.	1.6	17
128	Transcriptional Modulation of the Hippo Signaling Pathway by Drugs Used to Treat Bipolar Disorder and Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7164.	1.8	11
129	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. <i>Bipolar Disorders</i> , 2021, 23, 659-678.	1.1	27
130	Why do medications with little or no efficacy continue to be prescribed in the management of patients with bipolar disorder?. <i>Bipolar Disorders</i> , 2021, 23, 541-543.	1.1	2
131	Risk of cancer in bipolar disorder and the potential role of lithium: International collaborative systematic review and meta-analyses. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 126, 529-541.	2.9	23
132	Mood disorder and cancer onset: evidence from a population-based sample of Australian women. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 355-361.	0.9	1
133	An Investigation Into Miniaturised Closed-Loop DBS Devices. <i>IEEE Transactions on Medical Robotics and Bionics</i> , 2021, 3, 671-680.	2.1	3
134	The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. <i>Current Neuropharmacology</i> , 2021, 19, 1202-1224.	1.4	44
135	N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial. <i>EClinicalMedicine</i> , 2021, 38, 101005.	3.2	12
136	The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?. <i>Cytokine</i> , 2021, 144, 155593.	1.4	61
137	The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. <i>Pharmacological Research</i> , 2021, 170, 105729.	3.1	24
138	Polyphenols as adjunctive treatments in psychiatric and neurodegenerative disorders: Efficacy, mechanisms of action, and factors influencing inter-individual response. <i>Free Radical Biology and Medicine</i> , 2021, 172, 101-122.	1.3	19
139	Increased maternal mental health burden in a representative longitudinal community cohort coinciding with COVID-19 lockdown. <i>Australian Journal of Psychology</i> , 2021, 73, 578-585.	1.4	2
140	796ls Mindfulness a more effective intervention than Psychoeducation for reducing Bipolar Disorder-related symptoms of depression?. <i>International Journal of Epidemiology</i> , 2021, 50, .	0.9	0
141	The lipid paradox in neuroprogressive disorders: Causes and consequences. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 35-57.	2.9	10
142	Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder. <i>International Journal of Bipolar Disorders</i> , 2021, 9, 26.	0.8	6
143	Statins: Neurobiological underpinnings and mechanisms in mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 693-708.	2.9	15
144	Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain. <i>Journal of Clinical Medicine</i> , 2021, 10, 4095.	1.0	8

#	ARTICLE	IF	CITATIONS
145	Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial. <i>Journal of Psychiatric Research</i> , 2021, 142, 376-383.	1.5	1
146	Peripheral levels of C-reactive protein, tumor necrosis factor- α , interleukin-6, and interleukin-1 β across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability. <i>Brain, Behavior, and Immunity</i> , 2021, 97, 193-203.	2.0	80
147	A proof-of-concept study of maternal immune activation mediated induction of Toll-like receptor (TLR) and inflammasome pathways leading to neuroprogressive changes and schizophrenia-like behaviours in offspring. <i>European Neuropsychopharmacology</i> , 2021, 52, 48-61.	0.3	19
148	Translational evidence for the Inflammatory Response System (IRS)/Compensatory Immune Response System (CIRS) and neuroprogression theory of major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110343.	2.5	37
149	Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review. <i>Journal of Affective Disorders</i> , 2021, 295, 740-751.	2.0	33
150	Leveraging Convergence Science to Address Global Mental Health Challenges. , 2021, , 7-28.		1
151	Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry. <i>Molecular Neurobiology</i> , 2021, 58, 2158-2182.	1.9	48
152	Inflammatory versus Anti-Inflammatory Profiles in Major Depressive Disordersâ€”The Role of IL-17, IL-21, IL-23, IL-35 and Foxp3. <i>Journal of Personalized Medicine</i> , 2021, 11, 66.	1.1	29
153	Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: PÂ©ricarpe dâ€™appoint <i>Garcinia mangostana</i> Linn (mangoustan) pour la schizophrÃ©nie : un essai dâ€™efficacitÃ© de 24 semaines, Ã double insu, randomisÃ© et contrÃ© par placebo. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 354-366.	0.9	3
154	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. <i>Bipolar Disorders</i> , 2021, 23, 767-788.	1.1	32
155	Universal depression prevention: An umbrella review of meta-analyses. <i>Journal of Psychiatric Research</i> , 2021, 144, 483-493.	1.5	18
156	Deep learning for neuroimaging-based diagnosis and rehabilitation of Autism Spectrum Disorder: A review. <i>Computers in Biology and Medicine</i> , 2021, 139, 104949.	3.9	119
157	A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking. <i>European Neuropsychopharmacology</i> , 2021, 53, 120-126.	0.3	0
158	Anticonvulsant use and fracture: a case-control study. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2021, 21, 422-428.	0.1	0
159	Mindfulness-based online intervention to improve quality of life in late-stage bipolar disorder: A randomized clinical trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2021, 89, 830-844.	1.6	4
160	Dietary quality and nutrient intake in adults with obsessiveâ€”compulsive disorder. <i>BJPsych Open</i> , 2021, 7, .	0.3	4
161	FMT for psychiatric disorders: Following the brown brick road into the future. <i>Bipolar Disorders</i> , 2021, 23, 651-655.	1.1	8
162	Microdialysis and microperfusion electrodes in neurologic disease monitoring. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 52.	2.4	11

#	ARTICLE	IF	CITATIONS
163	Child and Parent Physical Activity, Sleep, and Screen Time During COVID-19 and Associations With Mental Health: Implications for Future Psycho-Cardiological Disease?. <i>Frontiers in Psychiatry</i> , 2021, 12, 774858.	1.3	13
164	The Mooa™D Study: protocol for a randomised controlled trial of A2 beta-casein only versus conventional dairy products in women with low mood. <i>Trials</i> , 2021, 22, 899.	0.7	1
165	Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis. <i>JAMA Network Open</i> , 2021, 4, e2140858.	2.8	14
166	Social isolation, social support and loneliness as predictors of cardiovascular disease incidence and mortality. <i>BMC Geriatrics</i> , 2021, 21, 711.	1.1	43
167	Psychographic Segmentation: Another Lever for Precision Population Brain Health. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 783297.	1.7	2
168	Fermented foods, the gut and mental health: a mechanistic overview with implications for depression and anxiety. <i>Nutritional Neuroscience</i> , 2020, 23, 659-671.	1.5	95
169	Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 14-21.	0.9	7
170	Unravelling facets of milk derived opioid peptides: a focus on gut physiology, fractures and obesity. <i>International Journal of Food Sciences and Nutrition</i> , 2020, 71, 36-49.	1.3	17
171	The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 775-783.	1.3	27
172	EPA and DHA as markers of nutraceutical treatment response in major depressive disorder. <i>European Journal of Nutrition</i> , 2020, 59, 2439-2447.	1.8	19
173	Are remitted affective disorders and familial risk of affective disorders associated with metabolic syndrome, inflammation and oxidative stress? â€“ a monozygotic twin study. <i>Psychological Medicine</i> , 2020, 50, 1736-1745.	2.7	12
174	S-Adenosylmethionine (SAME) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. <i>Psychopharmacology</i> , 2020, 237, 209-218.	1.5	19
175	Depression, stress and vascular function from childhood to adolescence: A longitudinal investigation. <i>General Hospital Psychiatry</i> , 2020, 62, 6-12.	1.2	13
176	The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101486.	0.9	11
177	Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive N-acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 159-172.	1.3	11
178	Differences in the immune-inflammatory profiles of unipolar and bipolar depression. <i>Journal of Affective Disorders</i> , 2020, 262, 8-15.	2.0	55
179	Impact of antipsychotic medication on IL6/STAT3 signaling axis in peripheral blood mononuclear cells of drug-naïve schizophrenia patients. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 64-69.	1.0	26
180	The role of microglia in neuroprogressive disorders: mechanisms and possible neurotherapeutic effects of induced ketosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109858.	2.5	26

#	ARTICLE	IF	CITATIONS
181	Drugs used to treat bipolar disorder act via microRNAs to regulate expression of genes involved in neurite outgrowth. <i>Journal of Psychopharmacology</i> , 2020, 34, 370-379.	2.0	15
182	TinyFSCV: FSCV for the Masses. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2020, 28, 133-142.	2.7	11
183	Opportunities in the Australian national education initiative for promoting mental health in schools. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 11-13.	2.7	7
184	Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 453-466.	1.3	58
185	Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled Trial. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 306-318.	0.9	9
186	Depression in the medically ill. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 346-366.	1.3	24
187	Endothelial dysfunction in neuroprogressive disorders—causes and suggested treatments. <i>BMC Medicine</i> , 2020, 18, 305.	2.3	53
188	Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study. <i>Diabetes Care</i> , 2020, 43, 3050-3060.	4.3	28
189	Health services research in mental health: The next frontier?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 955-956.	1.3	0
190	Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. <i>BMC Medicine</i> , 2020, 18, 261.	2.3	66
191	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. <i>Life Sciences</i> , 2020, 262, 118541.	2.0	12
192	Dietary tryptophan and bone health: a cross-sectional, population-based study. <i>Archives of Osteoporosis</i> , 2020, 15, 167.	1.0	6
193	The Associations between Dairy Product Consumption and Biomarkers of Inflammation, Adipocytokines, and Oxidative Stress in Children: A Cross-Sectional Study. <i>Nutrients</i> , 2020, 12, 3055.	1.7	5
194	The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2020, 276, 970-983.	2.0	43
195	Explanatory style in youth self-harm: an Indian qualitative study to inform intervention design. <i>Evidence-Based Mental Health</i> , 2020, 23, 100-106.	2.2	6
196	Transcriptional Effects of Psychoactive Drugs on Genes Involved in Neurogenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8333.	1.8	7
197	Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis. <i>JAMA Network Open</i> , 2020, 3, e2024335.	2.8	19
198	Bipolar disorders. <i>Lancet</i> , 2020, 396, 1841-1856.	6.3	419

#	ARTICLE	IF	CITATIONS
199	Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes. <i>FASEB Journal</i> , 2020, 34, 8787-8795.	0.2	111
200	Personality disorder increases risk of low quality of life among women with mental state disorders. <i>Comprehensive Psychiatry</i> , 2020, 102, 152193.	1.5	7
201	Validity of self-reported cancer: Comparison between self-report versus cancer registry records in the Geelong Osteoporosis Study. <i>Cancer Epidemiology</i> , 2020, 68, 101790.	0.8	8
202	The effect of combined treatment with SSRIs and renin-angiotensin system (RAS) drugs: A propensity score matched cohort study. <i>European Neuropsychopharmacology</i> , 2020, 32, 120-130.	0.3	4
203	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. <i>Life Sciences</i> , 2020, 258, 118166.	2.0	79
204	A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol. <i>BMC Psychiatry</i> , 2020, 20, 397.	1.1	7
205	Prebiotics, probiotics, fermented foods and cognitive outcomes: A meta-analysis of randomized controlled trials. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 118, 472-484.	2.9	50
206	Be You: A national education initiative to support the mental health of Australian children and young people. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 1061-1066.	1.3	9
207	Responsible innovation in technology for mental health care. <i>Lancet Psychiatry</i> , 2020, 7, 728-730.	3.7	7
208	Antihypertensive Drugs and Risk of Depression. <i>Hypertension</i> , 2020, 76, 1263-1279.	1.3	46
209	The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary. <i>Bipolar Disorders</i> , 2020, 22, 788-804.	1.1	61
210	Study protocol for the systematic review and meta-analyses of the association between schizophrenia and bone fragility. <i>BMJ Open</i> , 2020, 10, e041859.	0.8	2
211	Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than <i>Clostridium difficile</i> infection: a systematic review and meta-analysis. <i>Gut Microbes</i> , 2020, 12, 1854640.	4.3	81
212	Personality Disorder and Physical Health Comorbidities: A Link With Bone Health?. <i>Frontiers in Psychiatry</i> , 2020, 11, 602342.	1.3	4
213	The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. <i>Bipolar Disorders</i> , 2020, 22, 805-821.	1.1	87
214	Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. <i>Translational Psychiatry</i> , 2020, 10, 152.	2.4	102
215	Anti-inflammatory treatment of bipolar depression: promise and disappointment. <i>Lancet Psychiatry</i> , 2020, 7, 467-468.	3.7	9
216	Patterns of Association between Depressive Symptoms and Chronic Medical Morbidities in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1834-1841.	1.3	41

#	ARTICLE	IF	CITATIONS
217	A Randomized Controlled Trial of Transcultural Validation of Group-Based Psychosocial Intervention for Patients with Bipolar Disorder. <i>Psychiatry Research</i> , 2020, 290, 113139.	1.7	4
218	Effect of Aspirin vs Placebo on the Prevention of Depression in Older People. <i>JAMA Psychiatry</i> , 2020, 77, 1012.	6.0	47
219	Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 759-761.	1.3	6
220	Can Depression Be Prevented? If So, How?. <i>JAMA Psychiatry</i> , 2020, 77, 1095.	6.0	23
221	The interplay between oxidative stress and bioenergetic failure in neuropsychiatric illnesses: can we explain it and can we treat it?. <i>Molecular Biology Reports</i> , 2020, 47, 5587-5620.	1.0	29
222	Changing dynamics of psychoneuroimmunology during the COVID-19 pandemic. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 5, 100096.	1.3	23
223	Psychosocial Intervention With or Without Antipsychotic Medication for First-Episode Psychosis: A Randomized Noninferiority Clinical Trial. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	45
224	What is the potential of statins in the treatment of depression?. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 307-309.	1.4	0
225	Bridging the treatment gap: Psychedelics, prevention, pills and potions, psychotherapy and protest. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 221-222.	1.3	0
226	Lithium should be borne in mind: Five key reasons. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 659-663.	1.3	5
227	Bone health in bipolar disorder: a study protocol for a caseâ€“control study in Australia. <i>BMJ Open</i> , 2020, 10, e032821.	0.8	5
228	Interleukin-6 and total antioxidant capacity levels following <i>N</i> -acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2020, 32, 313-320.	1.0	3
229	The influence of stage of illness on functional outcomes after psychological treatment in bipolar disorder: A systematic review. <i>Bipolar Disorders</i> , 2020, 22, 666-692.	1.1	4
230	Induced Ketosis as a Treatment for Neuroprogressive Disorders: Food for Thought?. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 366-384.	1.0	28
231	Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. <i>Annals of Oncology</i> , 2020, 31, 369-376.	0.6	17
232	The embryology of psychosis. <i>Lancet Psychiatry</i> , 2020, 7, 219-220.	3.7	0
233	Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial. <i>Trials</i> , 2020, 21, 14.	0.7	10
234	Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies. <i>BMC Medicine</i> , 2020, 18, 21.	2.3	132

#	ARTICLE	IF	CITATIONS
235	Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. <i>Biological Psychiatry</i> , 2020, 88, 369-380.	0.7	209
236	Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin. <i>BMC Medicine</i> , 2020, 18, 16.	2.3	49
237	A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder. <i>Journal of Affective Disorders</i> , 2020, 265, 233-238.	2.0	12
238	Risk of dementia in bipolar disorder and the interplay of lithium: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 510-521.	2.2	80
239	The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross-sectional study. <i>Journal of Human Hypertension</i> , 2020, 34, 787-794.	1.0	25
240	Neurodevelopmental pathways in bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 112, 213-226.	2.9	59
241	Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e035080.	0.8	1
242	Studies on Haloperidol and Adjunctive $\hat{\pm}$ -Mangostin or Raw <i>Garcinia mangostana</i> Linn Pericarp on Bio-Behavioral Markers in an Immune-Inflammatory Model of Schizophrenia in Male Rats. <i>Frontiers in Psychiatry</i> , 2020, 11, 121.	1.3	9
243	Neurovegetative symptom subtypes in young people with major depressive disorder and their structural brain correlates. <i>Translational Psychiatry</i> , 2020, 10, 108.	2.4	20
244	Precision psychiatry with immunological and cognitive biomarkers: a multi-domain prediction for the diagnosis of bipolar disorder or schizophrenia using machine learning. <i>Translational Psychiatry</i> , 2020, 10, 162.	2.4	33
245	Finding reviewers: A crisis for journals and their authors. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 957-959.	1.3	4
246	Nutritional ketosis as an intervention to relieve astrogliosis: Possible therapeutic applications in the treatment of neurodegenerative and neuroprogressive disorders. <i>European Psychiatry</i> , 2020, 63, e8.	0.1	31
247	Lithium therapy and its interactions. <i>Australian Prescriber</i> , 2020, 43, 91-93.	0.5	8
248	Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 142-150.	1.1	9
249	A randomized controlled trial of MoodSwings 2.0: An internet-based self-management program for bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 28-39.	1.1	34
250	Does N-acetylcysteine improve behaviour in children with autism?: A mixed-methods analysis of the effects of N-acetylcysteine. <i>Journal of Intellectual and Developmental Disability</i> , 2019, 44, 474-480.	1.1	3
251	Association of depression with mortality in an elderly treated hypertensive population. <i>International Psychogeriatrics</i> , 2019, 31, 371-381.	0.6	11
252	The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. <i>Lancet Psychiatry</i> , 2019, 6, 735-744.	3.7	63

#	ARTICLE	IF	CITATIONS
253	Has the sun set for seasonal affective disorder and HPA axis studies? A systematic review and future prospects. <i>Journal of Affective Disorders</i> , 2019, 256, 584-593.	2.0	7
254	The open access mandate: Be careful what you wish for. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 1044-1046.	1.3	5
255	Beyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management. <i>Bipolar Disorders</i> , 2019, 21, 650-659.	1.1	19
256	The compensatory antioxidant response system with a focus on neuroprogressive disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 95, 109708.	2.5	19
257	Early intervention for bipolar disorder – “ Do current treatment guidelines provide recommendations for the early stages of the disorder?. <i>Journal of Affective Disorders</i> , 2019, 257, 669-677.	2.0	13
258	The case for improved care and provision of treatment for people with first-episode mania. <i>Lancet Psychiatry</i> , 2019, 6, 869-876.	3.7	46
259	Sample selection and reasons for non-participation in the PRedictors and Outcomes of incident FRACtures (PROFRAC) study. <i>Journal of Public Health Research</i> , 2019, 8, 1475.	0.5	3
260	The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized-controlled trials. <i>World Psychiatry</i> , 2019, 18, 308-324.	4.8	139
261	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 720-740.	1.1	71
262	ANZJP this month September 2019: Acculturating the brain?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 833-834.	1.3	0
263	A case of antibiotic-associated mania in a 67-year-old woman. <i>Bipolar Disorders</i> , 2019, 21, 670-672.	1.1	1
264	International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. <i>Psychotherapy and Psychosomatics</i> , 2019, 88, 263-273.	4.0	114
265	Mapping Cancer incidence across Western Victoria: the association with age, accessibility, and socioeconomic status among men and women. <i>BMC Cancer</i> , 2019, 19, 892.	1.1	9
266	Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities. <i>Pharmacological Research</i> , 2019, 148, 104450.	3.1	31
267	Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis – “ A possible therapeutic mechanism. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 766-777.	1.3	5
268	N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 555.	0.7	8
269	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 681-697.	1.0	28
270	Promotion of Wellbeing for Children of Parents With Mental Illness: A Model Protocol for Research and Intervention. <i>Frontiers in Psychiatry</i> , 2019, 10, 606.	1.3	20

#	ARTICLE	IF	CITATIONS
271	Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2019, 10, 605.	1.3	43
272	Shared pathways for neuroprogression and somatoprogession in neuropsychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 862-882.	2.9	74
273	Emerging role of innate B1 cells in the pathophysiology of autoimmune and neuroimmune diseases: Association with inflammation, oxidative and nitrosative stress and autoimmune responses. <i>Pharmacological Research</i> , 2019, 148, 104408.	3.1	35
274	First episode mania: we should have intervened earlier. <i>Lancet Psychiatry</i> , 2019, 6, 807-808.	3.7	0
275	Socioeconomic Deprivation, Adverse Childhood Experiences and Medical Disorders in Adulthood: Mechanisms and Associations. <i>Molecular Neurobiology</i> , 2019, 56, 5866-5890.	1.9	46
276	Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. <i>Microbial Biotechnology</i> , 2019, 13, 1032-1049.	0.9	34
277	A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. <i>BMC Medicine</i> , 2019, 17, 18.	2.3	73
278	Bipolar disorder and bone health: A systematic review. <i>Journal of Affective Disorders</i> , 2019, 249, 262-269.	2.0	30
279	Lessons from Iceland: Developing scalable and sustainable community approaches for the prevention of mental disorders in young Australians. <i>Mental Health and Prevention</i> , 2019, 15, 200166.	0.7	8
280	A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine (amphetamine) dependence. <i>Trials</i> , 2019, 20, 325.	0.7	14
281	Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 297-307.	0.9	5
282	Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2019, 77, 557-571.	2.6	59
283	Does stage of illness influence recovery-focused outcomes after psychological treatment in bipolar disorder? A systematic review protocol. <i>Systematic Reviews</i> , 2019, 8, 125.	2.5	6
284	An immune gate of depression – Early neuroimmune development in the formation of the underlying depressive disorder. <i>Pharmacological Reports</i> , 2019, 71, 1299-1307.	1.5	30
285	The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence. <i>Nutrients</i> , 2019, 11, 1196.	1.7	68
286	Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for a systematic review. <i>BMJ Open</i> , 2019, 9, e025640.	0.8	5
287	Biomarker-Guided Anti-inflammatory Therapies. <i>JAMA Psychiatry</i> , 2019, 76, 779.	6.0	15
288	Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study. <i>CNS Drugs</i> , 2019, 33, 685-694.	2.7	8

#	ARTICLE	IF	CITATIONS
289	Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: a protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e025145.	0.8	5
290	Supporting Engagement, Adherence, and Behavior Change in Online Dietary Interventions. <i>Journal of Nutrition Education and Behavior</i> , 2019, 51, 719-739.	0.3	17
291	Prevalence of depressive symptoms and its associated factors among healthy community-dwelling older adults living in Australia and the United States. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1208-1216.	1.3	56
292	Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. <i>Frontiers in Psychiatry</i> , 2019, 10, 103.	1.3	77
293	Variation in the prevalence of depression and patterns of association, sociodemographic and lifestyle factors in community-dwelling older adults in six low- and middle-income countries. <i>Journal of Affective Disorders</i> , 2019, 251, 218-226.	2.0	40
294	Buffering against maladaptive perfectionism in bipolar disorder: The role of self-compassion. <i>Journal of Affective Disorders</i> , 2019, 250, 132-139.	2.0	24
295	Association between solar insolation and a history of suicide attempts in bipolar I disorder. <i>Journal of Psychiatric Research</i> , 2019, 113, 1-9.	1.5	25
296	Diet and Depression—From Confirmation to Implementation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 842.	3.8	24
297	Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity — a consensus of the Biomarkers Task Force from the WFSBP. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 340-351.	1.3	20
298	Better research, better evidence, better access. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 97-98.	1.3	0
299	New drug candidates for bipolar disorder—A nation-wide population-based study. <i>Bipolar Disorders</i> , 2019, 21, 410-418.	1.1	19
300	Faecal microbiota transplants for depression — Who gives a crapsule?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 732-734.	1.3	13
301	Childbirth and prevention of bipolar disorder: an opportunity for change. <i>Lancet Psychiatry</i> , 2019, 6, 786-792.	3.7	14
302	Protocol update and statistical analysis plan for CADENCE-BZ: a randomized clinical trial to assess the efficacy of sodium benzoate as an adjunctive treatment in early psychosis. <i>Trials</i> , 2019, 20, 203.	0.7	2
303	The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 115.	1.3	16
304	A Neuroethics Framework for the Australian Brain Initiative. <i>Neuron</i> , 2019, 101, 365-369.	3.8	11
305	Development of a miniature device for emerging deep brain stimulation paradigms. <i>PLoS ONE</i> , 2019, 14, e0212554.	1.1	12
306	P.4.08 Metabolic syndrome, inflammation and oxidative stress as potential risk factors for affective disorders — a twin study. <i>European Neuropsychopharmacology</i> , 2019, 29, S706-S707.	0.3	0

#	ARTICLE	IF	CITATIONS
307	Improving functional outcomes in early-stage bipolar disorder: The protocol for the REsearch into COgnitive and behavioural VERsatility trial. <i>Microbial Biotechnology</i> , 2019, 13, 1470-1479.	0.9	10
308	Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?. <i>Metabolic Brain Disease</i> , 2019, 34, 385-415.	1.4	50
309	ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis. <i>Trials</i> , 2019, 20, 658.	0.7	7
310	The impact of urbanization on mood disorders. <i>Current Opinion in Psychiatry</i> , 2019, 32, 198-203.	3.1	36
311	New drug candidates for depression – a nationwide population-based study. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 68-77.	2.2	58
312	Association between childhood trauma exposure and pro-inflammatory cytokines in schizophrenia and bipolar-I disorder. <i>Psychological Medicine</i> , 2019, 49, 2736-2744.	2.7	22
313	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 2-16.	1.3	26
314	Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial. <i>Journal of Affective Disorders</i> , 2019, 245, 1007-1015.	2.0	42
315	Efficacy of adjunctive <i>Garcinia mangostana</i> Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 245-253.	0.9	8
316	The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: An integrative review of evidence, mechanisms, and clinical implications. <i>Pharmacological Research</i> , 2019, 139, 494-502.	3.1	42
317	Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. <i>British Journal of Psychiatry</i> , 2019, 214, 27-35.	1.7	54
318	Considerations when selecting pharmacotherapy for nicotine dependence. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 245-250.	0.9	0
319	The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study. <i>Journal of Affective Disorders</i> , 2019, 245, 1043-1051.	2.0	37
320	The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine. , 2019, , .		8
321	Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. <i>Microbial Biotechnology</i> , 2019, 13, 953-960.	0.9	19
322	The role of depression pharmacogenetic decision support tools in shared decision making. <i>Journal of Neural Transmission</i> , 2019, 126, 87-94.	1.4	21
323	Could Alzheimer’s Disease Originate in the Periphery and If So How So?. <i>Molecular Neurobiology</i> , 2019, 56, 406-434.	1.9	71
324	Mechanisms Underpinning the Polypharmacy Effects of Medications in Psychiatry. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 582-591.	1.0	19

#	ARTICLE	IF	CITATIONS
325	<i>N</i> -acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 391-400.	2.2	66
326	Differential effect of quetiapine and lithium on functional connectivity of the striatum in first episode mania. <i>Translational Psychiatry</i> , 2018, 8, 59.	2.4	59
327	Bipolar disorders. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18008.	18.1	518
328	Personality: Distraction or driver in the diagnosis of depression. <i>Personality and Mental Health</i> , 2018, 12, 126-130.	0.6	9
329	Health risks, needs and service delivery. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 105-106.	1.3	0
330	The subjective wellbeing profile of the "preiree"™ demographic: A cross-sectional study. <i>Maturitas</i> , 2018, 110, 111-117.	1.0	6
331	S204. NUTRITIONAL DEFICIENCIES AND CLINICAL CORRELATES IN FIRST-EPISODE PSYCHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S405-S405.	2.3	1
332	Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 90, 212-220.	2.9	34
333	The Endoplasmic Reticulum Stress Response in Neuroprogressive Diseases: Emerging Pathophysiological Role and Translational Implications. <i>Molecular Neurobiology</i> , 2018, 55, 8765-8787.	1.9	59
334	The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. <i>Sleep Medicine Reviews</i> , 2018, 41, 255-265.	3.8	85
335	Lithium and nephrotoxicity: Unravelling the complex pathophysiological threads of the lightest metal. <i>Nephrology</i> , 2018, 23, 897-903.	0.7	28
336	Selective Serotonin Reuptake Inhibitors (SSRIs) and Markers of Bone Turnover in Men. <i>Calcified Tissue International</i> , 2018, 103, 125-130.	1.5	15
337	Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer. <i>Cell Reports</i> , 2018, 22, 809-819.	2.9	32
338	Early Intervention in Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2018, 175, 411-426.	4.0	218
339	Distinguishing transient versus stable aspects of depression in New Zealand Pacific Island children using Generalizability Theory. <i>Journal of Affective Disorders</i> , 2018, 227, 698-704.	2.0	21
340	Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neuroprogressive diseases. <i>Behavioural Brain Research</i> , 2018, 341, 154-175.	1.2	114
341	Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. <i>Pharmacotherapy</i> , 2018, 38, 235-258.	1.2	60
342	Gender-specific risk factors for low bone mineral density in patients taking antipsychotics for psychosis. <i>Human Psychopharmacology</i> , 2018, 33, e2648.	0.7	11

#	ARTICLE	IF	CITATIONS
343	The Future of Psychiatry Commission. <i>Lancet Psychiatry</i> , 2018, 5, 13.	3.7	1
344	Multiple Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways Explain the Frequent Presence of Depression in Multiple Sclerosis. <i>Molecular Neurobiology</i> , 2018, 55, 6282-6306.	1.9	51
345	Nutritional Deficiencies and Clinical Correlates in First-Episode Psychosis: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2018, 44, 1275-1292.	2.3	61
346	Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol). <i>International Journal of Bipolar Disorders</i> , 2018, 6, 11.	0.8	10
347	The MHC/HLA Gene Complex in Major Psychiatric Disorders: Emerging Roles and Implications. <i>Current Behavioral Neuroscience Reports</i> , 2018, 5, 179-188.	0.6	19
348	Mitochondrial Agents for Bipolar Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 550-569.	1.0	31
349	Response to "Pitfalls of big data". <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 604-605.	1.3	0
350	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 97-170.	1.1	1,079
351	Youth Depression Alleviation—Augmentation with an anti-inflammatory agent (YoDA): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin. <i>Microbial Biotechnology</i> , 2018, 12, 45-54.	0.9	15
352	Falls and Depression in Men: A Population-Based Study. <i>American Journal of Men's Health</i> , 2018, 12, 14-18.	0.7	9
353	A Comparison of Neuroimaging Abnormalities in Multiple Sclerosis, Major Depression and Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): is There a Common Cause?. <i>Molecular Neurobiology</i> , 2018, 55, 3592-3609.	1.9	25
354	Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 250-254.	2.5	26
355	Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 24-38.	1.3	31
356	The limitations of using randomised controlled trials as a basis for developing treatment guidelines. <i>Evidence-Based Mental Health</i> , 2018, 21, 4-6.	2.2	62
357	Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists. <i>Molecular Neurobiology</i> , 2018, 55, 5767-5786.	1.9	114
358	Psychometric properties of a short form of the Center for Epidemiologic Studies Depression (CES-D-10) scale for screening depressive symptoms in healthy community dwelling older adults. <i>General Hospital Psychiatry</i> , 2018, 51, 118-125.	1.2	129
359	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 330-348.	1.3	32
360	Cognition in depression: Can we THINC-it better?. <i>Journal of Affective Disorders</i> , 2018, 225, 559-562.	2.0	27

#	ARTICLE	IF	CITATIONS
361	A neuro-immune, neuro-oxidative and neuro-nitrosative model of prenatal and postpartum depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 262-274.	2.5	42
362	Stress, Depression, and Inflammation: Molecular and Microglial Mechanisms. <i>Biological Psychiatry</i> , 2018, 83, 5-6.	0.7	24
363	Post-Operative Cognitive Dysfunction: An exploration of the inflammatory hypothesis and novel therapies. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 84, 116-133.	2.9	210
364	<i>Garcinia mangostana</i> Linn displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression: a bio-behavioral study in the Flinders Sensitive Line rat. <i>Metabolic Brain Disease</i> , 2018, 33, 467-480.	1.4	24
365	Pre-onset risk characteristics for mania among young people at clinical high risk for psychosis. <i>Schizophrenia Research</i> , 2018, 192, 345-350.	1.1	5
366	The role of hypernitrosylation in the pathogenesis and pathophysiology of neuroprogressive diseases. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 84, 453-469.	2.9	27
367	S219. RISK FACTORS FOR LOW BONE MINERAL DENSITY IN PATIENTS TAKING ANTIPSYCHOTICS. <i>Schizophrenia Bulletin</i> , 2018, 44, S411-S411.	2.3	0
368	Internet use by older adults with bipolar disorder: international survey results. <i>International Journal of Bipolar Disorders</i> , 2018, 6, 20.	0.8	13
369	Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. <i>BMC Nephrology</i> , 2018, 19, 305.	0.8	75
370	Medications With Depression as an Adverse Effect. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1815.	3.8	3
371	Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0. <i>Frontiers in Psychiatry</i> , 2018, 9, 641.	1.3	79
372	The SMILES trial: an important first step. <i>BMC Medicine</i> , 2018, 16, 237.	2.3	4
373	Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging. <i>Journal of Biological Chemistry</i> , 2018, 293, 17829-17837.	1.6	28
374	T159. ASSOCIATION BETWEEN VITAMIN D INSUFFICIENCY AND METABOLIC SYNDROME IN PATIENTS WITH PSYCHOTIC DISORDERS. <i>Schizophrenia Bulletin</i> , 2018, 44, S177-S178.	2.3	0
375	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i>, Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1173-1182.	1.3	18
376	Effect of Aspirin on Disability-free Survival in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018, 379, 1499-1508.	13.9	392
377	Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018, 379, 1519-1528.	13.9	591
378	Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018, 379, 1509-1518.	13.9	770

#	ARTICLE	IF	CITATIONS
379	Leaky brain in neurological and psychiatric disorders: Drivers and consequences. Australian and New Zealand Journal of Psychiatry, 2018, 52, 924-948.	1.3	90
380	Diet as a hot topic in psychiatry: a population-scale study of nutritional intake and inflammatory potential in severe mental illness. World Psychiatry, 2018, 17, 365-367.	4.8	102
381	Mental health information online: what we have learned from social media metrics in BuzzFeed's Mental Health Week. Trends in Psychiatry and Psychotherapy, 2018, 40, 326-336.	0.4	8
382	Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions - Improvement (CGI-S) scale in bipolar and major depressive disorder. European Psychiatry, 2018, 53, 17-22.	0.1	30
383	Ketamine and rapidly acting antidepressants: Breaking the speed of sound or light?. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1026-1029.	1.3	7
384	From culture to the brain. Australian and New Zealand Journal of Psychiatry, 2018, 52, 613-614.	1.3	0
385	Efficacy of online lifestyle interventions targeting lifestyle behaviour change in depressed populations: A systematic review. Australian and New Zealand Journal of Psychiatry, 2018, 52, 834-846.	1.3	28
386	Psychopathological Features of Bipolar Depression: Italian Validation of the Bipolar Depression Rating Scale (I-BDRS). Frontiers in Psychology, 2018, 9, 1047.	1.1	4
387	Economic evaluation of a dietary intervention for adults with major depression (the "SMILES" trial). BMC Public Health, 2018, 18, 599.	1.2	50
388	The impact of substance use disorders on recovery from bipolar depression: Results from the Systematic Treatment Enhancement Program for Bipolar Disorder psychosocial treatment trial. Australian and New Zealand Journal of Psychiatry, 2018, 52, 847-855.	1.3	9
389	Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Focus (American Tj ETQq1 1 0.784314 rgBT /Over 0,4	0.4	5
390	Web-based intervention to improve quality of life in late stage bipolar disorder (ORBIT): randomised controlled trial protocol. BMC Psychiatry, 2018, 18, 221.	1.1	29
391	AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation. Endocrinology, 2018, 159, 2884-2890.	1.4	16
392	Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression. Acta Neuropsychiatrica, 2018, 30, 334-341.	1.0	16
393	An investigation into closed-loop treatment of neurological disorders based on sensing mitochondrial dysfunction. Journal of NeuroEngineering and Rehabilitation, 2018, 15, 8.	2.4	10
394	"Is early intervention in bipolar disorder what it claims to be?" Malhi et al. Bipolar Disorders, 2018, 20, 181-183.	1.1	3
395	Adjunctive S-adenosylmethionine (SAME) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial. European Neuropsychopharmacology, 2018, 28, 1126-1136.	0.3	29
396	Role of IL-6/RORC/IL-22 axis in driving Th17 pathway mediated immunopathogenesis of schizophrenia. Cytokine, 2018, 111, 112-118.	1.4	28

#	ARTICLE	IF	CITATIONS
397	Depression and chronic diseases: Co-occurrence and communality of risk factors. <i>Journal of Affective Disorders</i> , 2018, 241, 461-468.	2.0	90
398	A review of the neurobiological underpinning of comorbid substance use and mood disorders. <i>Journal of Affective Disorders</i> , 2018, 241, 388-401.	2.0	33
399	Association Between Vitamin D Insufficiency and Metabolic Syndrome in Patients With Psychotic Disorders. <i>Psychiatry Investigation</i> , 2018, 15, 396-401.	0.7	8
400	Abstract A054: Loss of an androgen-inactivating and isoform-specific HSD17B4 splice form enables emergence of castration-resistant prostate cancer. , 2018, , .		0
401	The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease. <i>Molecular Neurobiology</i> , 2017, 54, 4432-4451.	1.9	191
402	A randomised, double blind, placebo-controlled trial of a fixed dose of <i>N</i> -acetyl cysteine in children with autistic disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 241-249.	1.3	48
403	Nitrosative Stress, Hypernitrosylation, and Autoimmune Responses to Nitrosylated Proteins: New Pathways in Neuroprogressive Disorders Including Depression and Chronic Fatigue Syndrome. <i>Molecular Neurobiology</i> , 2017, 54, 4271-4291.	1.9	82
404	A potential role for <i>N</i> -acetylcysteine in the management of methamphetamine dependence. <i>Drug and Alcohol Review</i> , 2017, 36, 153-159.	1.1	25
405	The prevalence, age distribution and comorbidity of personality disorders in Australian women. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 141-150.	1.3	32
406	Ethical considerations in preventive interventions for bipolar disorder. <i>Microbial Biotechnology</i> , 2017, 11, 104-112.	0.9	12
407	A systematic review and meta-analysis of prospective transition from major depression to bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 273-284.	2.2	90
408	Cognitive effects of adjunctive <i>N</i> -acetyl cysteine in psychosis. <i>Psychological Medicine</i> , 2017, 47, 866-876.	2.7	88
409	A model of the mitochondrial basis of bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 1-20.	2.9	118
410	Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. <i>Translational Psychiatry</i> , 2017, 7, e1011-e1011.	2.4	75
411	Towards recovery-oriented psychosocial interventions for bipolar disorder: Quality of life outcomes, stage-sensitive treatments, and mindfulness mechanisms. <i>Clinical Psychology Review</i> , 2017, 52, 148-163.	6.0	64
412	The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2017, 47, 1515-1527.	2.7	58
413	Psychosocial therapies for the adjunctive treatment of bipolar disorder in adults: Network meta-analysis. <i>British Journal of Psychiatry</i> , 2017, 210, 333-341.	1.7	109
414	Cognition in psychiatric disorders: from models to management. <i>Lancet Psychiatry</i> , 2017, 4, 173-175.	3.7	6

#	ARTICLE	IF	CITATIONS
415	Does irritability determine mood depending on age?. Australian and New Zealand Journal of Psychiatry, 2017, 51, 215-216.	1.3	8
416	The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes. Clinical Therapeutics, 2017, 39, 477-486.	1.1	69
417	Homocysteine as a peripheral biomarker in bipolar disorder: A meta-analysis. European Psychiatry, 2017, 43, 81-91.	0.1	33
418	A randomised controlled trial of dietary improvement for adults with major depression (the "SMILES" Tj ETQ0,0 0 rgBT /Overlock	2.3	595
419	A Review of the Theoretical and Biological Understanding of the Nocebo and Placebo Phenomena. Clinical Therapeutics, 2017, 39, 469-476.	1.1	59
420	Progressing MoodSwings. The upgrade and evaluation of MoodSwings 2.0: An online intervention for bipolar disorder. Contemporary Clinical Trials, 2017, 56, 18-24.	0.8	10
421	Quetiapine<i>v.</i>lithium in the maintenance phase following a first episode of mania: Randomised controlled trial. British Journal of Psychiatry, 2017, 210, 413-421.	1.7	53
422	Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools. BMC Psychiatry, 2017, 17, 60.	1.1	59
423	The effect of N-acetylcysteine (NAC) on human cognition " A systematic review. Neuroscience and Biobehavioral Reviews, 2017, 78, 44-56.	2.9	82
424	The new field of "precision psychiatry". BMC Medicine, 2017, 15, 80.	2.3	347
425	Do Sleep Disturbances Predict or Moderate the Response to Psychotherapy in Bipolar Disorder?. Journal of Nervous and Mental Disease, 2017, 205, 196-202.	0.5	5
426	Pattern of psychotropic medication use over two decades in Australian women. Australian and New Zealand Journal of Psychiatry, 2017, 51, 1212-1219.	1.3	5
427	508. Perturbations in the Apoptotic Pathway and Mitochondrial Network Dynamics in Peripheral Blood Mononuclear Cells from Bipolar Disorder Patients. Biological Psychiatry, 2017, 81, S206-S207.	0.7	0
428	Perturbations in the apoptotic pathway and mitochondrial network dynamics in peripheral blood mononuclear cells from bipolar disorder patients. Translational Psychiatry, 2017, 7, e1111-e1111.	2.4	62
429	Systematic assessment of environmental risk factors for bipolar disorder: an umbrella review of systematic reviews and meta-analyses. Bipolar Disorders, 2017, 19, 84-96.	1.1	108
430	Impact of irritability: a 2-year observational study of outpatients with bipolar I or schizoaffective disorder. Bipolar Disorders, 2017, 19, 184-197.	1.1	18
431	Functional Implications of the IL-23/IL-17 Immune Axis in Schizophrenia. Molecular Neurobiology, 2017, 54, 8170-8178.	1.9	29
432	Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities. Cell Chemical Biology, 2017, 24, 825-832.e6.	2.5	41

#	ARTICLE	IF	CITATIONS
433	Psychotropic pharmacogenetics –“ Distraction or destiny?. Australian and New Zealand Journal of Psychiatry, 2017, 51, 665-667.	1.3	3
434	Social and academic premorbid adjustment domains predict different functional outcomes among youth with first episode mania. Journal of Affective Disorders, 2017, 219, 133-140.	2.0	9
435	First-Episode Schizophrenia and Diabetes Risk. JAMA Psychiatry, 2017, 74, 761.	6.0	1
436	Defining melancholia: A core mood disorder. Bipolar Disorders, 2017, 19, 235-237.	1.1	34
437	Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. Australian and New Zealand Journal of Psychiatry, 2017, 51, 829-840.	1.3	75
438	Hierarchical estimation of neural activity through explicit identification of temporally synchronous spikes. Neurocomputing, 2017, 249, 299-313.	3.5	8
439	Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor. Acta Neuropsychiatrica, 2017, 29, 337-346.	1.0	25
440	Youth self-harm in low- and middle-income countries: Systematic review of the risk and protective factors. International Journal of Social Psychiatry, 2017, 63, 359-375.	1.6	73
441	Do Statins Have Antidepressant Effects?. CNS Drugs, 2017, 31, 335-343.	2.7	22
442	Association between bipolar spectrum disorder and bone health: a meta-analysis and systematic review protocol. BMJ Open, 2017, 7, e013981.	0.8	9
443	Cannabinoid receptors on peripheral leukocytes from patients with schizophrenia: Evidence for defective immunomodulatory mechanisms. Journal of Psychiatric Research, 2017, 87, 44-52.	1.5	20
444	Validation of a Portable Low-Power Deep Brain Stimulation Device Through Anxiolytic Effects in a Laboratory Rat Model. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2017, 25, 1365-1374.	2.7	16
445	Nutritional psychiatry: the present state of the evidence. Proceedings of the Nutrition Society, 2017, 76, 427-436.	0.4	229
446	Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder. Pharmacogenetics and Genomics, 2017, 27, 1-6.	0.7	12
447	Could Lithium in Drinking Water Reduce the Incidence of Dementia?. JAMA Psychiatry, 2017, 74, 983.	6.0	7
448	Defining disorders with permeable borders: you say bipolar, I say borderline!. Bipolar Disorders, 2017, 19, 320-323.	1.1	24
449	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 2017, 377, 1119-1131.	13.9	6,227
450	Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study. Translational Psychiatry, 2017, 7, e1220-e1220.	2.4	78

#	ARTICLE	IF	CITATIONS
451	Nâ€acetylcysteine in the treatment of craving in substance use disorders: Systematic review and metaâ€analysis. <i>American Journal on Addictions</i> , 2017, 26, 660-666.	1.3	58
452	Staging in bipolar disorder: from theoretical framework to clinical utility. <i>World Psychiatry</i> , 2017, 16, 236-244.	4.8	160
453	Getting RID of the blues: Formulating a Risk Index for Depression (RID) using structural equation modeling. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 1121-1133.	1.3	10
454	Priorities in the assessment and management of perinatal mood disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 1082-1084.	1.3	2
455	Solar insolation in springtime influences age of onset of bipolar I disorder. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 571-582.	2.2	24
456	Mixed mood: The not so united states?. <i>Bipolar Disorders</i> , 2017, 19, 242-245.	1.1	18
457	Clinical research and the medical research future fund. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 863-865.	1.3	1
458	338. Enabling Precision Psychiatry through â€omicsâ€™: From Biomarkers to Biological Pathways. <i>Biological Psychiatry</i> , 2017, 81, S138-S139.	0.7	3
459	980. Insulin is a State Biomarker in Major Depressive Disorder: A Systematic Review and Meta-Analysis. <i>Biological Psychiatry</i> , 2017, 81, S396-S397.	0.7	0
460	Is atypical depression simply a typical depression with unusual symptoms?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 868-871.	1.3	8
461	Personality disorder is an excess risk factor for physical multimorbidity among women with mental state disorders. <i>Psychiatry Research</i> , 2017, 257, 546-549.	1.7	9
462	Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study. <i>Advances in Integrative Medicine</i> , 2017, 4, 109-114.	0.4	3
463	Putting the CART before the horse?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 313-314.	1.3	0
464	International multi-site survey on the use of online support groups in bipolar disorder. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 473-476.	0.7	4
465	Indices of insulin resistance and glucotoxicity are not associated with bipolar disorder or major depressive disorder, but are differently associated with inflammatory, oxidative and nitrosative biomarkers. <i>Journal of Affective Disorders</i> , 2017, 222, 185-194.	2.0	11
466	Recalibrating the risks and benefits of lithium therapy. <i>British Journal of Psychiatry</i> , 2017, 211, 1-2.	1.7	11
467	The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 165.	0.7	11
468	Predictors for clinical deterioration of mental state in patients assessed by telephoneâ€based mental health triage. <i>International Journal of Mental Health Nursing</i> , 2017, 26, 226-237.	2.1	9

#	ARTICLE	IF	CITATIONS
469	Why so GLUMM? Detecting depression clusters through graphing lifestyle-environs using machine-learning methods (GLUMM). <i>European Psychiatry</i> , 2017, 39, 40-50.	0.1	18
470	Beyond the therapeutic shackles of the monoamines: New mechanisms in bipolar disorder biology. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 72, 73-86.	2.5	31
471	Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 31-46.	4.0	176
472	Emergency Department Youth Patients With Suicidal Ideation or Attempts: Predicting Suicide Attempts Through 18-Months of Follow-Up. <i>Suicide and Life-Threatening Behavior</i> , 2017, 47, 551-566.	0.9	25
473	Evaluation of Modified Patient Health Questionnaire-9 Teen in South African Adolescents. <i>Indian Journal of Psychological Medicine</i> , 2017, 39, 143-145.	0.6	9
474	Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. <i>ELife</i> , 2017, 6, .	2.8	83
475	The renin-angiotensin system: a possible new target for depression. <i>BMC Medicine</i> , 2017, 15, 144.	2.3	98
476	Online ethics: where will the interface of mental health and the internet lead us?. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 26.	0.8	16
477	Cognitive functioning following stabilisation from first episode mania. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 39.	0.8	3
478	Analyzing leukocyte telomere length in bipolar disorder: Authors' reply. <i>Revista Brasileira De Psiquiatria</i> , 2017, 39, 275-276.	0.9	1
479	Staging in bipolar disorder: one step closer to precision psychiatry. <i>Revista Brasileira De Psiquiatria</i> , 2017, 39, 88-89.	0.9	14
480	Plasma Levels of Tumor Necrosis Factor Superfamily Molecules Are Increased in Bipolar Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2017, 15, 269-275.	0.9	17
481	Youth depression alleviation: the Fish Oil Youth Depression Study (YoDA): A randomized, double-blind, placebo-controlled treatment trial. <i>Microbial Biotechnology</i> , 2016, 10, 290-299.	0.9	16
482	Editorial (Thematic Issue : Gut Permeability and the Microbiome: Emerging Roles in CNS Function in) <i>Trends in Microbiology</i> , 2017, 25, 106-107.	8.9	0
483	Speaker 4: Michael Berk. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, 41-42.	1.0	0
484	Shortened telomere length in bipolar disorder: a comparison of the early and late stages of disease. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 281-286.	0.9	43
485	Study protocol for a systematic review of evidence for lifestyle interventions targeting smoking, sleep, alcohol/other drug use, physical activity, and healthy diet in people with bipolar disorder. <i>Systematic Reviews</i> , 2016, 5, 106.	2.5	9
486	Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study. <i>PLoS ONE</i> , 2016, 11, e0151417.	1.1	22

#	ARTICLE	IF	CITATIONS
487	Biological models of mental illness: implications for therapy development. Medical Journal of Australia, 2016, 204, 339-340.	0.8	1
488	Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology. Current Molecular Medicine, 2016, 16, 119-136.	0.6	22
489	PM485. Association between erythrocyte membrane fatty acids and psychopathology in individuals at ultra-high risk for psychosis. International Journal of Neuropsychopharmacology, 2016, 19, 76-76.	1.0	0
490	PM486. Disrupting GluR2-GAPDH Interaction Affects Axon and Dendrite Development. International Journal of Neuropsychopharmacology, 2016, 19, 76-77.	1.0	0
491	Speaker 3: Michael Berk, Australia. International Journal of Neuropsychopharmacology, 2016, 19, 26-26.	1.0	0
492	Speaker 2: Olivia Dean, Australia. International Journal of Neuropsychopharmacology, 2016, 19, 41-41.	1.0	0
493	PS229. The use of statins for the treatment of depression in patients with acute coronary syndrome. International Journal of Neuropsychopharmacology, 2016, 19, 83-84.	1.0	0
494	Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatrica Scandinavica, 2016, 134, 91-103.	2.2	173
495	Integrating Early Intervention for Borderline Personality Disorder and Mood Disorders. Harvard Review of Psychiatry, 2016, 24, 330-341.	0.9	74
496	Mitochondrial dysfunction in bipolar disorder: Evidence, pathophysiology and translational implications. Neuroscience and Biobehavioral Reviews, 2016, 68, 694-713.	2.9	121
497	SPECIFIC MOOD SYMPTOMS CONFER RISK FOR SUBSEQUENT SUICIDAL IDEATION IN BIPOLAR DISORDER WITH AND WITHOUT SUICIDE ATTEMPT HISTORY: MULTI-WAVE DATA FROM STEP-BD. Depression and Anxiety, 2016, 33, 464-472.	2.0	27
498	ASPREE-D: Aspirin for the prevention of depression in the elderly. International Psychogeriatrics, 2016, 28, 1741-1748.	0.6	17
499	PM396. Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness. International Journal of Neuropsychopharmacology, 2016, 19, 44-44.	1.0	0
500	Antioxidant treatments for schizophrenia. The Cochrane Library, 2016, 2016, CD008919.	1.5	49
501	Angiotensin Converting Enzyme Inhibitors and Risk of Mood Disorders. Psychotherapy and Psychosomatics, 2016, 85, 250-252.	4.0	19
502	Mental health system development in Asia: Does Australia have a role?. Australian and New Zealand Journal of Psychiatry, 2016, 50, 834-841.	1.3	3
503	Bias in emerging biomarkers for bipolar disorder. Psychological Medicine, 2016, 46, 2287-2297.	2.7	50
504	Associations between DNA Damage, DNA Base Excision Repair Gene Variability and Alzheimer's Disease Risk. Dementia and Geriatric Cognitive Disorders, 2016, 41, 152-171.	0.7	27

#	ARTICLE	IF	CITATIONS
505	A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 65, 185-194.	2.9	256
506	Leptin in bipolar disorder: A systematic review and meta-analysis. <i>European Psychiatry</i> , 2016, 35, 1-7.	0.1	32
507	The prevalence and age of onset of psychiatric disorders in Australian men. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 678-684.	1.3	11
508	Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. <i>American Journal of Psychiatry</i> , 2016, 173, 575-587.	4.0	315
509	Affective instability and the course of bipolar depression: Results from the STEP-BD randomised controlled trial of psychosocial treatment. <i>British Journal of Psychiatry</i> , 2016, 208, 352-358.	1.7	21
510	Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. <i>Journal of Affective Disorders</i> , 2016, 200, 235-242.	2.0	104
511	Cognitive remission: a novel objective for the treatment of major depression?. <i>BMC Medicine</i> , 2016, 14, 9.	2.3	177
512	Hyperthermia for Major Depressive Disorder?. <i>JAMA Psychiatry</i> , 2016, 73, 1095.	6.0	0
513	A cluster analytic approach to identifying predictors and moderators of psychosocial treatment for bipolar depression: Results from STEP-BD. <i>Journal of Affective Disorders</i> , 2016, 203, 152-157.	2.0	9
514	Autobiographical memory dysfunctions in depressive disorders. <i>Psychiatry and Clinical Neurosciences</i> , 2016, 70, 100-108.	1.0	29
515	Bipolar disorder: defining symptoms and comorbidities – Authors' reply. <i>Lancet, The</i> , 2016, 388, 869-870.	6.3	4
516	Online information seeking by patients with bipolar disorder: results from an international multisite survey. <i>International Journal of Bipolar Disorders</i> , 2016, 4, 17.	0.8	35
517	The impact of HLA-G 3' UTR variants and sHLA-G on risk and clinical correlates of schizophrenia. <i>Human Immunology</i> , 2016, 77, 1166-1171.	1.2	14
518	C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2016, 3, 1147-1156.	3.7	169
519	The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 395.	0.7	16
520	Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. <i>CNS Spectrums</i> , 2016, 21, 184-198.	0.7	159
521	Electrical resistance increases at the tissue-electrode interface as an early response to nucleus accumbens deep brain stimulation. , 2016, 2016, 1814-1817.		4
522	Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women. <i>JAMA Psychiatry</i> , 2016, 73, 947.	6.0	74

#	ARTICLE	IF	CITATIONS
523	Internet use by patients with bipolar disorder: Results from an international multisite survey. <i>Psychiatry Research</i> , 2016, 242, 388-394.	1.7	36
524	N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. <i>BMC Psychiatry</i> , 2016, 16, 320.	1.1	34
525	Population prevalence of personality disorder and associations with physical health comorbidities and health care service utilization: A review.. <i>Personality Disorders: Theory, Research, and Treatment</i> , 2016, 7, 136-146.	1.0	75
526	An ISBD perspective on the sociocultural challenges of managing bipolar disorder: A content analysis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1096-1103.	1.3	2
527	Immuno-psychiatry: an agenda for clinical practice and innovative research. <i>BMC Medicine</i> , 2016, 14, 173.	2.3	51
528	Unified selective sorting approach to analyse multi-electrode extracellular data. <i>Scientific Reports</i> , 2016, 6, 28533.	1.6	9
529	Nucleus accumbens deep-brain stimulation efficacy in ACTH-pretreated rats: alterations in mitochondrial function relate to antidepressant-like effects. <i>Translational Psychiatry</i> , 2016, 6, e842-e842.	2.4	34
530	Medical burden, body mass index and the outcome of psychosocial interventions for bipolar depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 667-677.	1.3	16
531	Mental health for all Australians. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 301-302.	1.3	0
532	Harnessing the potential of community-based participatory research approaches in bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2016, 4, 4.	0.8	33
533	Is there a nexus between mental and bone health?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 829-830.	1.3	7
534	Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2016, 18, 89-101.	1.1	153
535	The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases. <i>Molecular Neurobiology</i> , 2016, 53, 1195-1219.	1.9	115
536	A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up study. <i>European Psychiatry</i> , 2016, 31, 20-28.	0.1	25
537	Depression as a risk factor for fracture in women: A 10 year longitudinal study. <i>Journal of Affective Disorders</i> , 2016, 192, 34-40.	2.0	25
538	Statin and Aspirin Use and the Risk of Mood Disorders among Men. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw008.	1.0	21
539	Depression is a risk factor for incident coronary heart disease in women: An 18-year longitudinal study. <i>Journal of Affective Disorders</i> , 2016, 196, 117-124.	2.0	77
540	The addition of depression to the Framingham Risk Equation model for predicting coronary heart disease risk in women. <i>Preventive Medicine</i> , 2016, 87, 115-120.	1.6	8

#	ARTICLE	IF	CITATIONS
541	Bias in Peripheral Depression Biomarkers. <i>Psychotherapy and Psychosomatics</i> , 2016, 85, 81-90.	4.0	46
542	T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 64, 83-100.	2.9	74
543	Trajectory and predictors of quality of life in first episode psychotic mania. <i>Journal of Affective Disorders</i> , 2016, 195, 148-155.	2.0	12
544	Physical health comorbidities in women with personality disorder: Data from the Geelong Osteoporosis Study. <i>European Psychiatry</i> , 2016, 34, 29-35.	0.1	21
545	South African adolescents' beliefs about depression. <i>International Journal of Social Psychiatry</i> , 2016, 62, 198-200.	1.6	7
546	The trajectory of cognitive functioning following first episode mania: A 12-month follow-up study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 1186-1197.	1.3	13
547	DNA methylation and the social gradient of osteoporotic fracture: A conceptual model. <i>Bone</i> , 2016, 84, 204-212.	1.4	27
548	Regulators of mitochondrial complex I activity: A review of literature and evaluation in postmortem prefrontal cortex from patients with bipolar disorder. <i>Psychiatry Research</i> , 2016, 236, 148-157.	1.7	8
549	Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression. <i>Drugs and Aging</i> , 2016, 33, 21-25.	1.3	50
550	Theory of mind in major depressive disorder: A meta-analysis. <i>Journal of Affective Disorders</i> , 2016, 191, 49-55.	2.0	218
551	The Putative Role of Viruses, Bacteria, and Chronic Fungal Biotxin Exposure in the Genesis of Intractable Fatigue Accompanied by Cognitive and Physical Disability. <i>Molecular Neurobiology</i> , 2016, 53, 2550-2571.	1.9	28
552	The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders. <i>Molecular Neurobiology</i> , 2016, 53, 4638-4658.	1.9	49
553	Gut dysbiosis in mania: A viable therapeutic target?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 185-185.	1.3	0
554	Citalopram and sertraline exposure compromises embryonic bone development. <i>Molecular Psychiatry</i> , 2016, 21, 656-664.	4.1	23
555	Bipolar disorder. <i>Lancet, The</i> , 2016, 387, 1561-1572.	6.3	1,100
556	C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. <i>Molecular Psychiatry</i> , 2016, 21, 554-564.	4.1	254
557	Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. <i>Molecular Neurobiology</i> , 2016, 53, 2927-2935.	1.9	40
558	Single-Nucleotide Polymorphisms of Genes Involved in Repair of Oxidative DNA Damage and the Risk of Recurrent Depressive Disorder. <i>Medical Science Monitor</i> , 2016, 22, 4455-4474.	0.5	16

#	ARTICLE	IF	CITATIONS
559	Fusing Data Mining, Machine Learning and Traditional Statistics to Detect Biomarkers Associated with Depression. PLoS ONE, 2016, 11, e0148195.	1.1	63
560	Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis. PLoS ONE, 2016, 11, e0148429.	1.1	28
561	Into the Bowels of Depression: Unravelling Medical Symptoms Associated with Depression by Applying Machine-Learning Techniques to a Community Based Population Sample. PLoS ONE, 2016, 11, e0167055.	1.1	17
562	Gut Permeability and Microbiota in Parkinson's Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways. Current Pharmaceutical Design, 2016, 22, 6142-6151.	0.9	77
563	The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer's Disease. Current Pharmaceutical Design, 2016, 22, 6152-6166.	0.9	179
564	The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome. Current Pharmaceutical Design, 2016, 22, 6058-6075.	0.9	47
565	Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes. Current Pharmaceutical Design, 2016, 22, 6087-6106.	0.9	77
566	The Putative Use of Lithium in Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 853-861.	0.7	45
567	Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary View. Journal of Medical Internet Research, 2016, 18, e323.	2.1	590
568	Predicting Risk of Suicide Attempt Using History of Physical Illnesses From Electronic Medical Records. JMIR Mental Health, 2016, 3, e19.	1.7	25
569	N-Acetylcysteine in Depressive Symptoms and Functionality. Journal of Clinical Psychiatry, 2016, 77, e457-e466.	1.1	93
570	Editorial: Gut Permeability and the Microbiome: Emerging Roles in CNS Function in Health and Disease. Current Pharmaceutical Design, 2016, 22, 1-3.	0.9	36
571	Editorial: Gut Permeability and the Microbiome: Emerging Roles in CNS Function in Health and Disease. Current Pharmaceutical Design, 2016, , .	0.9	1
572	Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Medicine, 2015, 13, 289.	2.3	233
573	Who cares about carers?. Australian and New Zealand Journal of Psychiatry, 2015, 49, 936-937.	1.3	1
574	From risk to remediation. Australian and New Zealand Journal of Psychiatry, 2015, 49, 857-858.	1.3	0
575	N-Acetylcysteine for Huntington's?. Australian and New Zealand Journal of Psychiatry, 2015, 49, 1071-1072.	1.3	2
576	Symptoms of Depression and Difficulty Initiating Sleep from Early Adolescence to Early Adulthood: A Longitudinal Study. Sleep, 2015, 38, 1599-1606.	0.6	42

#	ARTICLE	IF	CITATIONS
577	Strengthening the role of convergence science in medicine. <i>Convergent Science Physical Oncology</i> , 2015, 1, 026001.	2.6	5
578	Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder. <i>Psychiatry Investigation</i> , 2015, 12, 349.	0.7	22
579	Editorial (Thematic Issue: Mitochondrial Dysfunction and Its Relation to Translocator Protein,) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10</i> 353-354.	1.1	0
580	N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 12-24.	0.9	78
581	Mechanisms Underlying Neurocognitive Dysfunctions in Recurrent Major Depression. <i>Medical Science Monitor</i> , 2015, 21, 1535-1547.	0.5	70
582	Tobacco Use in Bipolar Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 1-11.	0.9	49
583	Effects of Persisting Emotional Impact from Child Abuse and Norepinephrine Transporter Genetic Variation on Antidepressant Efficacy in Major Depression: A Pilot Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 53-61.	0.9	5
584	Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 03-12.	0.9	38
585	The Use of Mixed Methods in Drug Discovery. , 2015, , 59-74.		5
586	Three Paths to Drug Discovery in Psychiatry. <i>American Journal of Psychiatry</i> , 2015, 172, 412-414.	4.0	18
587	Treatment Implications of Predominant Polarity and the Polarity Index: A Comprehensive Review. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu079-pyu079.	1.0	34
588	Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. <i>Psychiatry Research</i> , 2015, 230, 982-983.	1.7	11
589	Depolarising bipolarity: Clinical considerations. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 767-769.	1.3	4
590	Milk Consumption and the Risk for Incident Major Depressive Disorder. <i>Psychotherapy and Psychosomatics</i> , 2015, 84, 384-386.	4.0	12
591	Wireless Optogenetics: An Exploration of Portable Microdevices for Small Animal Photostimulation. <i>Procedia Technology</i> , 2015, 20, 225-230.	1.1	4
592	N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study. <i>Redox Report</i> , 2015, 20, 215-222.	1.4	57
593	Excessive daytime sleepiness and metabolic syndrome: a cross-sectional study. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 244-252.	1.5	27
594	Influence of birth cohort on age of onset cluster analysis in bipolar I disorder. <i>European Psychiatry</i> , 2015, 30, 99-105.	0.1	28

#	ARTICLE	IF	CITATIONS
595	RF rectifiers for EM power harvesting in a Deep Brain Stimulating device. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2015, 38, 157-172.	1.4	10
596	The association between use of antidepressants and bone quality using quantitative heel ultrasound. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 437-443.	1.3	14
597	Evolution of adolescent mental health in a rapidly changing socioeconomic environment: A review of mental health studies in adolescents in India over last 10 years. <i>Asian Journal of Psychiatry</i> , 2015, 13, 3-12.	0.9	41
598	Association of paraoxonase (PON)1 activity, glutathione S-transferase GST T1/M1 and STin.2 polymorphisms with comorbidity of tobacco use disorder and mood disorders. <i>Neuroscience Letters</i> , 2015, 585, 132-137.	1.0	14
599	The impact of maternal smoking during pregnancy on depressive and anxiety behaviors in children: the Norwegian Mother and Child Cohort Study. <i>BMC Medicine</i> , 2015, 13, 24.	2.3	61
600	Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1819-1835.	0.8	82
601	Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2015, 62, 18-26.	1.3	70
602	Prospective progression from high-prevalence disorders to bipolar disorder: Exploring characteristics of pre-illness stages. <i>Journal of Affective Disorders</i> , 2015, 183, 45-48.	2.0	33
603	A Cost-effectiveness model to Guide Health policy in Bipolar Disorder Treatment. <i>Value in Health</i> , 2015, 18, A122.	0.1	0
604	Sarcopenia and the Common Mental Disorders: a Potential Regulatory Role of Skeletal Muscle on Brain Function?. <i>Current Osteoporosis Reports</i> , 2015, 13, 351-357.	1.5	65
605	A brief review of exercise, bipolar disorder, and mechanistic pathways. <i>Frontiers in Psychology</i> , 2015, 6, 147.	1.1	54
606	The association between attributions of responsibility for motor vehicle accidents and patient satisfaction: a study within a no-fault injury compensation system. <i>Clinical Rehabilitation</i> , 2015, 29, 500-508.	1.0	14
607	Evolution of optogenetic microdevices. <i>Neurophotonics</i> , 2015, 2, 031206.	1.7	26
608	Personality disorder and population mental health. <i>Lancet Psychiatry</i> , the, 2015, 2, 201-202.	3.7	18
609	Online mindfulness-based intervention for late-stage bipolar disorder: pilot evidence for feasibility and effectiveness. <i>Journal of Affective Disorders</i> , 2015, 178, 46-51.	2.0	57
610	Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness. <i>Psychiatry Research</i> , 2015, 226, 368-375.	1.7	16
611	An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations. <i>Advances in Integrative Medicine</i> , 2015, 2, 49-55.	0.4	15
612	Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome and tobacco use disorder. <i>Journal of Affective Disorders</i> , 2015, 179, 148-155.	2.0	27

#	ARTICLE	IF	CITATIONS
613	Personality disorders and physical comorbidities in adults from the United States: data from the National Epidemiologic Survey on Alcohol and Related Conditions. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2015, 50, 807-820.	1.6	53
614	Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 927-939.	1.5	19
615	A shared framework for the common mental disorders and Non-Communicable Disease: key considerations for disease prevention and control. <i>BMC Psychiatry</i> , 2015, 15, 15.	1.1	90
616	Psychiatric disorders, psychotropic medication use and falls among women: an observational study. <i>BMC Psychiatry</i> , 2015, 15, 75.	1.1	40
617	Oxidant/antioxidant imbalance is an inherent feature of depression. <i>BMC Psychiatry</i> , 2015, 15, 71.	1.1	28
618	Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. <i>BMC Medicine</i> , 2015, 13, 28.	2.3	121
619	The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. <i>BMC Medicine</i> , 2015, 13, 68.	2.3	186
620	Cognitive impairment in first-episode mania: a systematic review of the evidence in the acute and remission phases of the illness. <i>International Journal of Bipolar Disorders</i> , 2015, 3, 9.	0.8	57
621	Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: An accelerated aging biomarker?. <i>Journal of Affective Disorders</i> , 2015, 182, 64-69.	2.0	47
622	Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 294-321.	2.9	350
623	The gut microbiome and diet in psychiatry. <i>Current Opinion in Psychiatry</i> , 2015, 28, 1-6.	3.1	301
624	Instruments that prospectively predict bipolar disorder – A systematic review. <i>Journal of Affective Disorders</i> , 2015, 179, 65-73.	2.0	14
625	Influence of light exposure during early life on the age of onset of bipolar disorder. <i>Journal of Psychiatric Research</i> , 2015, 64, 1-8.	1.5	39
626	Chronic fatigue syndrome: what is it and how to treat?. <i>Lancet Psychiatry</i> , 2015, 2, 1044-1045.	3.7	5
627	The use of statins for the treatment of depression in patients with acute coronary syndrome. <i>Translational Psychiatry</i> , 2015, 5, e620-e620.	2.4	33
628	Optimizing delivery of recovery-oriented online self-management strategies for bipolar disorder: a review. <i>Bipolar Disorders</i> , 2015, 17, 115-127.	1.1	47
629	N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study. <i>CNS Drugs</i> , 2015, 29, 801-809.	2.7	59
630	Nonsuicidal self-injury in Indian adolescents: Nonexistent or unacknowledged?. <i>International Journal of Social Psychiatry</i> , 2015, 61, 516-517.	1.6	11

#	ARTICLE	IF	CITATIONS
631	Excessive daytime sleepiness and falls among older men and women: cross-sectional examination of a population-based sample. <i>BMC Geriatrics</i> , 2015, 15, 74.	1.1	45
632	Antimanic-like activity of candesartan in mice: Possible involvement of antioxidant, anti-inflammatory and neurotrophic mechanisms. <i>European Neuropsychopharmacology</i> , 2015, 25, 2086-2097.	0.3	27
633	Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. <i>Translational Psychiatry</i> , 2015, 5, e495-e495.	2.4	48
634	The Classification of Biomarkers. <i>JAMA Psychiatry</i> , 2015, 72, 1056.	6.0	5
635	Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2015, 101, 15-21.	1.0	28
636	Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial. <i>European Psychiatry</i> , 2015, 30, 975-982.	0.1	24
637	C.01.02 Epidemiology of suicide in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2015, 25, S661.	0.3	0
638	Evaluating discussion board engagement in the MoodSwings online self-help program for bipolar disorder: protocol for an observational prospective cohort study. <i>BMC Psychiatry</i> , 2015, 15, 243.	1.1	9
639	Radio frequency energy harvesting from a feeding source in a passive deep brain stimulation device for murine preclinical research. <i>Medical Engineering and Physics</i> , 2015, 37, 1020-1026.	0.8	3
640	Transcultural adaption and validation of the Spanish version of the Bipolar Depression Rating Scale (BDRS-S). <i>Journal of Affective Disorders</i> , 2015, 172, 110-115.	2.0	9
641	Fetal programming of schizophrenia: Select mechanisms. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 49, 90-104.	2.9	62
642	Mitochondrial dysfunction in schizophrenia: Pathways, mechanisms and implications. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 48, 10-21.	2.9	214
643	The association between dietary patterns, diabetes and depression. <i>Journal of Affective Disorders</i> , 2015, 174, 215-224.	2.0	66
644	Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. <i>Molecular Psychiatry</i> , 2015, 20, 695-702.	4.1	128
645	STin2 VNTR polymorphism is associated with comorbid tobacco use and mood disorders. <i>Journal of Affective Disorders</i> , 2015, 172, 347-354.	2.0	13
646	Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. <i>Molecular Psychiatry</i> , 2015, 20, 152-153.	4.1	99
647	The relationships between insomnia, sleep apnoea and depression: Findings from the American National Health and Nutrition Examination Survey, 2005-2008. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 156-170.	1.3	62
648	Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 57, 69-75.	2.5	29

#	ARTICLE	IF	CITATIONS
649	Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. <i>Molecular Psychiatry</i> , 2015, 20, 1108-1119.	4.1	200
650	A comparison of schizophrenia, schizoaffective disorder, and bipolar disorder: Results from the Second Australian national psychosis survey. <i>Journal of Affective Disorders</i> , 2015, 172, 30-37.	2.0	44
651	A randomized head to head trial of MoodSwings.net.au: An internet based self-help program for bipolar disorder. <i>Journal of Affective Disorders</i> , 2015, 171, 13-21.	2.0	62
652	Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. <i>Journal of Affective Disorders</i> , 2015, 172, 55-62.	2.0	76
653	Mitochondrial Dysfunction in the Pathophysiology of Bipolar Disorder: Effects of Pharmacotherapy. <i>Mini-Reviews in Medicinal Chemistry</i> , 2015, 15, 355-365.	1.1	35
654	Restless Leg Syndrome Associated with Atypical Antipsychotics: Current Status, Pathophysiology, and Clinical Implications. <i>Current Drug Safety</i> , 2015, 10, 98-105.	0.3	17
655	Prevalence of Cardiovascular and Metabolic Events in Patients Prescribed Clozapine: A Retrospective Observational, Clinical Cohort Study. <i>Current Drug Safety</i> , 2015, 10, 125-131.	0.3	16
656	Effects of Asenapine in Bipolar I Patients Meeting Proxy Criteria for Moderate-to-Severe Mixed Major Depressive Episodes. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 728-734.	1.1	29
657	Nocebo Effects in the Treatment of Major Depression. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 702-711.	1.1	28
658	Effects of N-Acetyl Cysteine on Suicidal Ideation in Bipolar Depression. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e665-e665.	1.1	11
659	Abstract 2478: A mAb within vivo therapeutic activity against spontaneous breast tumors in FVB-neuN mice recognizes SLP-2. , 2015, , .		0
660	Beta-lactam antibiotics as a possible novel therapy for managing epilepsy and autism, a case report and review of literature. <i>Iranian Journal of Child Neurology</i> , 2015, 9, 99-102.	0.2	11
661	The association between major depressive disorder, use of antidepressants and bone mineral density (BMD) in men. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2015, 15, 177-85.	0.1	18
662	Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. <i>Revista Brasileira De Psiquiatria</i> , 2014, 36, 293-297.	0.9	27
663	Systematic review of N-acetylcysteine in the treatment of addictions. <i>Revista Brasileira De Psiquiatria</i> , 2014, 36, 168-175.	0.9	63
664	Stress, Inflammation, and Cellular Vulnerability during Early Stages of Affective Disorders: Biomarker Strategies and Opportunities for Prevention and Intervention. <i>Frontiers in Psychiatry</i> , 2014, 5, 34.	1.3	48
665	Targeting classical IL-6 signalling or IL-6<i>trans</i>-signalling in depression?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 495-512.	1.5	118
666	The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 during myocardial ischemia/reperfusion in a model of rats with depression. <i>BMC Psychiatry</i> , 2014, 14, 349.	1.1	54

#	ARTICLE	IF	CITATIONS
667	Construct validity of the Experiences of Therapy Questionnaire (ETQ). <i>BMC Psychiatry</i> , 2014, 14, 369.	1.1	8
668	Prevention of Schizophrenia--Will a Broader Prevention Agenda Support This Aim?. <i>Schizophrenia Bulletin</i> , 2014, 40, 237-239.	2.3	11
669	SLC6A4STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: a case control study. <i>BMC Genetics</i> , 2014, 15, 78.	2.7	13
670	Statin use and risk of depression: a Swedish national cohort study. <i>BMC Psychiatry</i> , 2014, 14, 348.	1.1	66
671	Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. <i>Molecular Psychiatry</i> , 2014, 19, 317-324.	4.1	58
672	Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity. <i>Redox Report</i> , 2014, 19, 232-241.	1.4	7
673	The impact of past direct-personal traumatic events on 12-month outcome in first episode psychotic mania: Trauma and early psychotic mania. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 1017-1024.	1.3	12
674	Attributions of responsibility and recovery within a no-fault insurance compensation system.. <i>Rehabilitation Psychology</i> , 2014, 59, 247-255.	0.7	15
675	Socio-demographic, lifestyle and psychological predictors of benzodiazepine and z-hypnotic use patterns. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 107-116.	0.7	23
676	A Royal gift to prevention efforts. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 110-111.	1.3	9
677	Association between attributions of responsibility for motor vehicle crashes, depressive symptoms, and return to work.. <i>Rehabilitation Psychology</i> , 2014, 59, 376-385.	0.7	13
678	Do Comorbid Anxiety Disorders Moderate the Effects of Psychotherapy for Bipolar Disorder? Results From STEP-BD. <i>American Journal of Psychiatry</i> , 2014, 171, 178-186.	4.0	54
679	Depression following fracture in women: a study of age-matched cohorts: Table 1. <i>BMJ Open</i> , 2014, 4, e004226.	0.8	28
680	Pop, heavy metal and the blues: secondary analysis of persistent organic pollutants (POP), heavy metals and depressive symptoms in the NHANES National Epidemiological Survey. <i>BMJ Open</i> , 2014, 4, e005142-e005142.	0.8	48
681	Investigating the predictive validity of an emergency department mental health triage tool. <i>Australian Journal of Cancer Nursing</i> , 2014, 16, 11-18.	0.8	4
682	Development of a Compact Rectenna for Wireless Powering of a Head-Mountable Deep Brain Stimulation Device. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2014, 2, 1-13.	2.2	38
683	Extreme attributions predict suicidal ideation and suicide attempts in bipolar disorder: prospective data from STEP-BD. <i>World Psychiatry</i> , 2014, 13, 95-96.	4.8	8
684	Biological phenotypes underpin the psychosomatic symptoms of somatization, depression, and chronic fatigue syndrome. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 83-97.	2.2	92

#	ARTICLE	IF	CITATIONS
685	Risk stratification using data from electronic medical records better predicts suicide risks than clinician assessments. <i>BMC Psychiatry</i> , 2014, 14, 76.	1.1	119
686	The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial. <i>Trials</i> , 2014, 15, 425.	0.7	11
687	Antidepressant pharmacogenetics. <i>Current Opinion in Psychiatry</i> , 2014, 27, 43-51.	3.1	40
688	Genetic polymorphisms in glutathione-S-transferases are associated with anxiety and mood disorders in nicotine dependence. <i>Psychiatric Genetics</i> , 2014, 24, 87-93.	0.6	18
689	Diagnosing bipolar disorder: Defining thresholds and setting boundaries. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 500-504.	1.3	16
690	Age at onset, course of illness and response to psychotherapy in bipolar disorder: results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). <i>Psychological Medicine</i> , 2014, 44, 3455-3467.	2.7	29
691	The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives. <i>Psychotherapy and Psychosomatics</i> , 2014, 83, 70-88.	4.0	93
692	Psychiatric disorders in primary care. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 497-499.	1.3	2
693	Navigating therapeutic waters with a faulty diagnostic compass. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 1075-1076.	1.3	1
694	Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism "smoking interactions differentially predict the odds of major depression and bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 159, 23-30.	2.0	68
695	A Head-to-Head Comparison of Aripiprazole and Risperidone for Safety and Treating Autistic Disorders, a Randomized Double Blind Clinical Trial. <i>Child Psychiatry and Human Development</i> , 2014, 45, 185-192.	1.1	97
696	Th17 Pathway-Mediated Immunopathogenesis of Schizophrenia: Mechanisms and Implications. <i>Schizophrenia Bulletin</i> , 2014, 40, 1412-1421.	2.3	102
697	Role of Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways in the Etiology of Depression: Therapeutic Implications. <i>CNS Drugs</i> , 2014, 28, 1-10.	2.7	75
698	OxNASH Score Correlates with Histologic Features and Severity of Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1617-1624.	1.1	40
699	Predominant polarity as a course specifier for bipolar disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2014, 163, 56-64.	2.0	74
700	The Glutathione System: A New Drug Target in Neuroimmune Disorders. <i>Molecular Neurobiology</i> , 2014, 50, 1059-1084.	1.9	164
701	Biomarkers and clinical staging in psychiatry. <i>World Psychiatry</i> , 2014, 13, 211-223.	4.8	243
702	The predictive validity of bipolar at-risk (prodromal) criteria in help-seeking adolescents and young adults: a prospective study. <i>Bipolar Disorders</i> , 2014, 16, 493-504.	1.1	103

#	ARTICLE	IF	CITATIONS
703	Staging systems in bipolar disorder: an international society for Bipolar Disorders Task Force Report. Acta Psychiatrica Scandinavica, 2014, 130, 354-363.	2.2	175
704	Association between alcohol consumption and self-reported depression among elderly Australian men. Geriatric Mental Health Care, 2014, 2, 3-8.	0.3	13
705	P.3.e.001 Clozapine alone and in combination with N-acetylcysteine reverses social isolation rearing induced serotonergic metabolism. European Neuropsychopharmacology, 2014, 24, S563-S564.	0.3	1
706	Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Molecular Psychiatry, 2014, 19, 750-751.	4.1	135
707	Data Integration Protocol In Ten-steps (DIPIT): A new standard for medical researchers. Methods, 2014, 69, 237-246.	1.9	14
708	Relationship between membrane fatty acids and cognitive symptoms and information processing in individuals at ultra-high risk for psychosis. Schizophrenia Research, 2014, 158, 39-44.	1.1	22
709	Predicting bipolar disorder on the basis of phenomenology: implications for prevention and early intervention. Bipolar Disorders, 2014, 16, 455-470.	1.1	40
710	Paraoxonase 1 status and interactions between Q192R functional genotypes by smoking contribute significantly to total plasma radical trapping antioxidant potential. Neuroscience Letters, 2014, 581, 46-51.	1.0	6
711	Adipokines as emerging depression biomarkers: A systematic review and meta-analysis. Journal of Psychiatric Research, 2014, 59, 28-37.	1.5	98
712	Atypical antipsychotic agents; Peas in a pod or chalk and cheese?. BMC Medicine, 2014, 12, .	2.3	2
713	Caspase 3 Inactivation Protects Against Hepatic Cell Death and Ameliorates Fibrogenesis in a Diet-Induced NASH Model. Digestive Diseases and Sciences, 2014, 59, 1197-1206.	1.1	98
714	Affective and Content Analysis of Online Depression Communities. IEEE Transactions on Affective Computing, 2014, 5, 217-226.	5.7	161
715	The Emerging Role of Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/cfs). Molecular Neurobiology, 2014, 49, 741-756.	1.9	87
716	Lifestyle medicine for depression. BMC Psychiatry, 2014, 14, 107.	1.1	265
717	Food policies for physical and mental health. BMC Psychiatry, 2014, 14, 132.	1.1	59
718	Lovastatin for the adjunctive treatment of schizophrenia: A preliminary randomized double-blind placebo-controlled trial. Psychiatry Research, 2014, 219, 431-435.	1.7	33
719	Suicidal ideation and physical illness: Does the link lie with depression?. Journal of Affective Disorders, 2014, 152-154, 422-426.	2.0	33
720	Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries. Australian and New Zealand Journal of Psychiatry, 2014, 48, 512-529.	1.3	119

#	ARTICLE	IF	CITATIONS
721	Prevalence of excessive daytime sleepiness in a sample of the Australian adult population. <i>Sleep Medicine</i> , 2014, 15, 348-354.	0.8	58
722	The association between poor dental health and depression: findings from a large-scale, population-based study (the NHANES study). <i>General Hospital Psychiatry</i> , 2014, 36, 266-270.	1.2	51
723	Castelli risk indexes 1 and 2 are higher in major depression but other characteristics of the metabolic syndrome are not specific to mood disorders. <i>Life Sciences</i> , 2014, 102, 65-71.	2.0	52
724	Temporal Order Assessment in Patients with Bipolar Disorder. <i>Procedia, Social and Behavioral Sciences</i> , 2014, 126, 216.	0.5	0
725	Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma. <i>Journal of Surgical Research</i> , 2014, 186, 29-38.	0.8	60
726	A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. <i>Psychoneuroendocrinology</i> , 2014, 43, 52-61.	1.3	26
727	Atopic disorders and depression: Findings from a large, population-based study. <i>Journal of Affective Disorders</i> , 2014, 155, 261-265.	2.0	70
728	Comparison of self-report and structured clinical interview in the identification of depression. <i>Comprehensive Psychiatry</i> , 2014, 55, 866-869.	1.5	96
729	Impact of comorbid anxiety disorders and obsessive-compulsive disorder on 24-month clinical outcomes of bipolar I disorder. <i>Journal of Affective Disorders</i> , 2014, 166, 243-248.	2.0	29
730	Relationship between sunlight and the age of onset of bipolar disorder: An international multisite study. <i>Journal of Affective Disorders</i> , 2014, 167, 104-111.	2.0	43
731	Oxidative & nitrosative stress in depression: Why so much stress?. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 45, 46-62.	2.9	324
732	The impact of insight in a first-episode mania with psychosis population on outcome at 18 months. <i>Journal of Affective Disorders</i> , 2014, 167, 74-79.	2.0	6
733	Quality of life in bipolar and schizoaffective disorder – A naturalistic approach. <i>Comprehensive Psychiatry</i> , 2014, 55, 1540-1545.	1.5	16
734	Application of the Gradient Boosted method in randomised clinical trials: Participant variables that contribute to depression treatment efficacy of duloxetine, SSRIs or placebo. <i>Journal of Affective Disorders</i> , 2014, 168, 284-293.	2.0	16
735	Stage managing bipolar disorder. <i>Bipolar Disorders</i> , 2014, 16, 471-477.	1.1	129
736	The Efficacy of Adjunctive N-Acetylcysteine in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 628-636.	1.1	142
737	Relationship Between Diet and Mental Health in Children and Adolescents: A Systematic Review. <i>American Journal of Public Health</i> , 2014, 104, e31-e42.	1.5	428
738	Assessing Regional Cerebral Blood Flow in Depression Using 320-Slice Computed Tomography. <i>PLoS ONE</i> , 2014, 9, e107735.	1.1	24

#	ARTICLE	IF	CITATIONS
739	Excessive Daytime Sleepiness and Body Composition: A Population-Based Study of Adults. PLoS ONE, 2014, 9, e112238.	1.1	19
740	Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial. Clinical Psychopharmacology and Neuroscience, 2014, 12, 180-188.	0.9	46
741	Abstract 2551: B cells induced during CD4+T-cell mediated destruction of primary tumors in neuN mice produce mAbs that are capable of inhibiting spontaneous tumor growth. , 2014, , .		0
742	Abstract A85: Passenger genes on tumor-associated amplicons function as tumor rejection antigens. , 2014, , .		0
743	Evidence for the existence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with and without abdominal discomfort (irritable bowel) syndrome. Neuroendocrinology Letters, 2014, 35, 445-53.	0.2	16
744	The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Molecular Psychiatry, 2013, 18, 595-606.	4.1	434
745	Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia. Medical Gas Research, 2013, 3, 11.	1.2	22
746	Tobacco smoking predicts depression and poorer quality of life in heart disease. BMC Cardiovascular Disorders, 2013, 13, 35.	0.7	34
747	Altered cardiac autonomic nervous function in depression. BMC Psychiatry, 2013, 13, 187.	1.1	88
748	The association between diet quality, dietary patterns and depression in adults: a systematic review. BMC Psychiatry, 2013, 13, 175.	1.1	270
749	A randomised, controlled trial of a dietary intervention for adults with major depression (the Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.1	52
750	Gender differences in first episode psychotic mania. BMC Psychiatry, 2013, 13, 82.	1.1	19
751	Evaluation of the acceptability and usefulness of an information website for caregivers of people with bipolar disorder. BMC Medicine, 2013, 11, 162.	2.3	38
752	The DSM-5: Hyperbole, Hope or Hypothesis?. BMC Medicine, 2013, 11, 128.	2.3	14
753	Physical comorbidities in men with mood and anxiety disorders: a population-based study. BMC Medicine, 2013, 11, 110.	2.3	37
754	The effects of apoptosis vulnerability markers on the myocardium in depression after myocardial infarction. BMC Medicine, 2013, 11, 32.	2.3	38
755	Coenzyme Q10 Depletion in Medical and Neuropsychiatric Disorders: Potential Repercussions and Therapeutic Implications. Molecular Neurobiology, 2013, 48, 883-903.	1.9	81
756	Oxidative stress and inflammatory markers are associated with depression and nicotine dependence. Neuroscience Letters, 2013, 544, 136-140.	1.0	87

#	ARTICLE	IF	CITATIONS
757	Maternal and Early Postnatal Nutrition and Mental Health of Offspring by Age 5 Years: A Prospective Cohort Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 1038-1047.	0.3	234
758	Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression. <i>Pharmacological Reports</i> , 2013, 65, 1647-1654.	1.5	74
759	Clusters of personality traits and psychological symptoms associated with later benzodiazepine prescriptions in the general population: The HUNT Cohort Study. <i>Addictive Behaviors</i> , 2013, 38, 2575-2580.	1.7	14
760	Quantitative Heel Ultrasound (QUS) measures of bone quality in association with mood and anxiety disorders. <i>Journal of Affective Disorders</i> , 2013, 146, 395-400.	2.0	17
761	Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 321-332.	1.3	193
762	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. <i>American Journal of Psychiatry</i> , 2013, 170, 1249-1262.	4.0	579
763	To a broader concept of remission: Rating the health-related quality of life in bipolar disorder. <i>Journal of Affective Disorders</i> , 2013, 150, 673-676.	2.0	6
764	Emerging pharmacotherapy for cancer patients with cognitive dysfunction. <i>BMC Neurology</i> , 2013, 13, 153.	0.8	25
765	N-acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats. <i>Metabolic Brain Disease</i> , 2013, 28, 687-696.	1.4	37
766	So depression is an inflammatory disease, but where does the inflammation come from?. <i>BMC Medicine</i> , 2013, 11, 200.	2.3	993
767	Gastro oesophageal reflux disease (GORD)-related symptoms and its association with mood and anxiety disorders and psychological symptomology: a population-based study in women. <i>BMC Psychiatry</i> , 2013, 13, 194.	1.1	16
768	Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. <i>International Journal of Bipolar Disorders</i> , 2013, 1, 10.	0.8	28
769	Alcohol consumption and body composition in a population-based sample of elderly Australian men. <i>Aging Clinical and Experimental Research</i> , 2013, 25, 183-192.	1.4	30
770	Potential Mechanisms of Action of Lithium in Bipolar Disorder. <i>CNS Drugs</i> , 2013, 27, 135-153.	2.7	337
771	How cigarette smoking may increase the risk of anxiety symptoms and anxiety disorders: a critical review of biological pathways. <i>Brain and Behavior</i> , 2013, 3, 302-326.	1.0	126
772	Selective Serotonin Reuptake Inhibitors Inhibit Human Osteoclast and Osteoblast Formation and Function. <i>Biological Psychiatry</i> , 2013, 74, 32-39.	0.7	95
773	Socioeconomic status and quality of life in population-based Australian men: data from the Geelong Osteoporosis Study. <i>Australian and New Zealand Journal of Public Health</i> , 2013, 37, 226-232.	0.8	18
774	Zinc for treating of children and adolescents with attention-deficit hyperactivity disorder: a systematic review of randomized controlled clinical trials. <i>European Journal of Clinical Nutrition</i> , 2013, 67, 122-124.	1.3	29

#	ARTICLE	IF	CITATIONS
775	Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo. Australian and New Zealand Journal of Psychiatry, 2013, 47, 347-354.	1.3	23
776	Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants. Current Medical Research and Opinion, 2013, 29, 827-833.	0.9	3
777	Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels. Behavioural Brain Research, 2013, 242, 76-83.	1.2	31
778	The promise of N-acetylcysteine in neuropsychiatry. Trends in Pharmacological Sciences, 2013, 34, 167-177.	4.0	359
779	Putative neuroprotective agents in neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 42, 135-145.	2.5	88
780	Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. Brain, Behavior, and Immunity, 2013, 30, 156-167.	2.0	150
781	Neurocognitive functioning in the prodrome of mania – an exploratory study. Journal of Affective Disorders, 2013, 147, 441-445.	2.0	41
782	Development of a measure quantifying adverse psychotherapeutic ingredients: The Experiences of Therapy Questionnaire (ETQ). Psychiatry Research, 2013, 206, 293-301.	1.7	32
783	Extreme attributions predict transition from depression to mania or hypomania in bipolar disorder. Journal of Psychiatric Research, 2013, 47, 1329-1336.	1.5	22
784	The sick role, illness cognitions and outcomes in bipolar disorder. Journal of Affective Disorders, 2013, 146, 146-149.	2.0	16
785	Treatment response for acute depression is not associated with number of previous episodes: Lack of evidence for a clinical staging model for major depressive disorder. Journal of Affective Disorders, 2013, 150, 344-349.	2.0	18
786	Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: Implications for the pathways to chronic depression and neuroprogression. Journal of Affective Disorders, 2013, 149, 23-29.	2.0	83
787	Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. Journal of Affective Disorders, 2013, 150, 923-930.	2.0	101
788	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 2013, 15, 1-44.	1.1	740
789	A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior. BMC Medicine, 2013, 11, 64.	2.3	62
790	In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatrica Scandinavica, 2013, 127, 344-354.	2.2	179
791	Targeting the mitochondrial electron transport chain in autism, a systematic review and synthesis of a novel therapeutic approach. Mitochondrion, 2013, 13, 515-519.	1.6	31
792	Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 42, 101-114.	2.5	66

#	ARTICLE	IF	CITATIONS
793	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 154-219.	1.3	344
794	The chemistry and biological activities of N-acetylcysteine. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 4117-4129.	1.1	620
795	Exercising the worry away: How inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 573-584.	2.9	115
796	Dietary intake of fish and PUFA, and clinical depressive and anxiety disorders in women. <i>British Journal of Nutrition</i> , 2013, 109, 2059-2066.	1.2	83
797	DSM-5 mixed specifier for manic episodes: Evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. <i>Journal of Affective Disorders</i> , 2013, 150, 378-383.	2.0	60
798	Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 42, 1-4.	2.5	128
799	Lifestyle management of unipolar depression. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 38-54.	2.2	88
800	The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1336-1345.	2.9	73
801	Differences between first episode schizophrenia and schizoaffective disorder. <i>Schizophrenia Research</i> , 2013, 147, 169-174.	1.1	18
802	Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. <i>BMC Medicine</i> , 2013, 11, 74.	2.3	163
803	Diet quality and mental health problems in adolescents from East London: a prospective study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2013, 48, 1297-1306.	1.6	71
804	DSM-5: a collection of psychiatrist views on the changes, controversies, and future directions. <i>BMC Medicine</i> , 2013, 11, 202.	2.3	86
805	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 334-385.	1.3	480
806	Contextualising the biology of psychiatry within its social environment. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 889-890.	1.3	0
807	Prevention of common mental disorders: What can we learn from those who have gone before and where do we go next?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 920-929.	1.3	75
808	Is "Depression"™ the new "Neurosis"™?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 297-298.	1.3	7
809	Psychomotor depressive symptoms may differentially respond to venlafaxine. <i>International Clinical Psychopharmacology</i> , 2013, 28, 121-126.	0.9	13
810	The relationship between excessive daytime sleepiness and depressive and anxiety disorders in women. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 772-778.	1.3	45

#	ARTICLE	IF	CITATIONS
811	The need for specialist services for serious and recurrent mood disorders. Australian and New Zealand Journal of Psychiatry, 2013, 47, 815-818.	1.3	4
812	Lipid-Induced Toxicity Stimulates Hepatocytes to Release Angiogenic Microparticles That Require Vanin-1 for Uptake by Endothelial Cells. Science Signaling, 2013, 6, ra88.	1.6	177
813	Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. British Journal of Psychiatry, 2013, 202, 243-245.	1.7	204
814	Neuropsychiatric presentation of Lyme disease in Australia. Australian and New Zealand Journal of Psychiatry, 2013, 47, 397-398.	1.3	3
815	Clinical Characteristics and Smoking Cessation. Addictive Disorders and Their Treatment, 2013, 12, 158-165.	0.5	9
816	A Low Power Micro Deep Brain Stimulation Device for Murine Preclinical Research. IEEE Journal of Translational Engineering in Health and Medicine, 2013, 1, 1500109-1500109.	2.2	20
817	Design and analysis of an antenna for wireless energy harvesting in a head-mountable DBS device. , 2013, 2013, 3078-81.		8
818	Development of an online intervention for bipolar disorder. www.moodswings.net.au. Psychology, Health and Medicine, 2013, 18, 155-165.	1.3	31
819	A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. Australian and New Zealand Journal of Psychiatry, 2013, 47, 564-568.	1.3	50
820	Pharmacological management of unipolar depression. Acta Psychiatrica Scandinavica, 2013, 127, 6-23.	2.2	33
821	The nocebo effect: A clinicians guide. Australian and New Zealand Journal of Psychiatry, 2013, 47, 617-623.	1.3	39
822	High impact child abuse may predict risk of elevated suicidality during antidepressant initiation. Australian and New Zealand Journal of Psychiatry, 2013, 47, 1191-1195.	1.3	8
823	Obesity and the relationship with positive and negative affect. Australian and New Zealand Journal of Psychiatry, 2013, 47, 477-482.	1.3	28
824	Diagnosis of myalgic encephalomyelitis: where are we now?. Expert Opinion on Medical Diagnostics, 2013, 7, 221-225.	1.6	9
825	Depression, diet and exercise. Medical Journal of Australia, 2013, 199, S21-3.	0.8	38
826	Efficacy and Adverse Effects of Venlafaxine in Children and Adolescents with ADHD: A Systematic Review of Non-controlled and Controlled Trials. Reviews on Recent Clinical Trials, 2013, 8, 2-8.	0.4	63
827	Deserves a hearing? A case report of remitting tinnitus with N-acetyl cysteine. African Journal of Psychiatry, 2013, 16, 238, 240.	0.1	1
828	Extreme Attributions Predict the Course of Bipolar Depression. Journal of Clinical Psychiatry, 2013, 74, 249-255.	1.1	21

#	ARTICLE	IF	CITATIONS
829	Treatment of bipolar depression. Medical Journal of Australia, 2013, 199, S32-5.	0.8	6
830	Treatment of bipolar depression. Medical Journal of Australia, 2013, 198, 139-139.	0.8	1
831	Difficult to treat depression. Medical Journal of Australia, 2013, 199, S4-5.	0.8	2
832	The Impact of Smoking in Adolescence on Early Adult Anxiety Symptoms and the Relationship between Infant Vulnerability Factors for Anxiety and Early Adult Anxiety Symptoms: The TOPP Study. PLoS ONE, 2013, 8, e63252.	1.1	35
833	Safe and effective use of lithium. Australian Prescriber, 2013, 36, 18-21.	0.5	16
834	Hyponatraemia: An Audit of Aged Psychiatry Patients Taking SSRIs and SNRIs. Current Drug Safety, 2013, 8, 175-180.	0.3	15
835	N-acetylcysteine Versus Placebo for Treating Nail Biting, a Double Blind Randomized Placebo Controlled Clinical Trial. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2013, 12, 223-228.	1.1	53
836	Clock face drawing test performance in children with ADHD. Basic and Clinical Neuroscience, 2013, 4, 50-6.	0.3	3
837	Complementary Medicine, Exercise, Meditation, Diet, and Lifestyle Modification for Anxiety Disorders: A Review of Current Evidence. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-20.	0.5	60
838	Adipocyte hypertrophy is associated with lysosomal permeability both in vivo and in vitro: role in adipose tissue inflammation. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E597-E606.	1.8	47
839	Is Australian psychiatry getting SHIP shape?. Australian and New Zealand Journal of Psychiatry, 2012, 46, 801-802.	1.3	2
840	Preventive strategies in depression: gathering evidence for risk factors and potential interventions. British Journal of Psychiatry, 2012, 201, 339-341.	1.7	30
841	Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Laboratory Investigation, 2012, 92, 713-723.	1.7	131
842	The role of alprazolam for the treatment of panic disorder in Australia. Australian and New Zealand Journal of Psychiatry, 2012, 46, 212-224.	1.3	22
843	Acceptance and commitment therapy for treatment-resistant depression. Australian and New Zealand Journal of Psychiatry, 2012, 46, 1198-1199.	1.3	10
844	Palliative models of care for later stages of mental disorder: maximizing recovery, maintaining hope, and building morale. Australian and New Zealand Journal of Psychiatry, 2012, 46, 92-99.	1.3	50
845	Commentary on "Palliative models of care for later stages of mental disorder: Maximising recovery, maintaining hope and building morale". Australian and New Zealand Journal of Psychiatry, 2012, 46, 276-278.	1.3	5
846	Red Meat Consumption and Mood and Anxiety Disorders. Psychotherapy and Psychosomatics, 2012, 81, 196-198.	4.0	49

#	ARTICLE	IF	CITATIONS
847	A Comparison of Inflammatory Markers in Depressed and Nondepressed Smokers. <i>Nicotine and Tobacco Research</i> , 2012, 14, 540-546.	1.4	46
848	Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder. <i>Current Pharmaceutical Design</i> , 2012, 18, 358-375.	0.9	70
849	Lipidomic Profiling of Serum and Pancreatic Fluid in Chronic Pancreatitis. <i>Pancreas</i> , 2012, 41, 518-522.	0.5	26
850	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of <i>Clinical Practice</i> . <i>Clinical Practice (London, England)</i> 2012; 16(10): 617-619.	0.0	50
851	Is the safety of lithium no longer in the balance?. <i>Lancet, The</i> , 2012, 379, 690-692.	6.3	38
852	Inflammation-Related Disorders in the Tryptophan Catabolite Pathway in Depression and Somatization. <i>Advances in Protein Chemistry and Structural Biology</i> , 2012, 88, 27-48.	1.0	52
853	Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. <i>Molecular Psychiatry</i> , 2012, 17, 1150-1152.	4.1	107
854	ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. <i>Translational Psychiatry</i> , 2012, 2, e198-e198.	2.4	61
855	Co-morbid cardiovascular disease and depression: sequence of disease onset is linked to mental but not physical self-rated health. Results from a cross-sectional, population-based study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2012, 47, 1145-1151.	1.6	24
856	Effects of N-acetyl cysteine on cognitive function in bipolar disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2012, 66, 514-517.	1.0	45
857	Deep brain stimulation for treatment-resistant depression: Efficacy, safety and mechanisms of action. <i>Neuroscience and Biobehavioral Reviews</i> , 2012, 36, 1920-1933.	2.9	117
858	Increased IgA and IgM responses against gut commensals in chronic depression: Further evidence for increased bacterial translocation or leaky gut. <i>Journal of Affective Disorders</i> , 2012, 141, 55-62.	2.0	364
859	Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 1058-1067.	1.3	82
860	Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 132-135.	2.5	26
861	Biological underpinnings of the commonalities in depression, somatization, and Chronic Fatigue Syndrome. <i>Medical Hypotheses</i> , 2012, 78, 752-756.	0.8	42
862	Pain and the relationship with mood and anxiety disorders and psychological symptoms. <i>Journal of Psychosomatic Research</i> , 2012, 72, 452-456.	1.2	41
863	Dietary selenium and major depression: a nested case-control study. <i>Complementary Therapies in Medicine</i> , 2012, 20, 119-123.	1.3	85
864	Is diagnosis enough to guide interventions in mental health? Using case formulation in clinical practice. <i>BMC Medicine</i> , 2012, 10, 111.	2.3	130

#	ARTICLE	IF	CITATIONS
865	Cigarette smoking, nicotine dependence and anxiety disorders: a systematic review of population-based, epidemiological studies. <i>BMC Medicine</i> , 2012, 10, 123.	2.3	157
866	Using lithium as a neuroprotective agent in patients with cancer. <i>BMC Medicine</i> , 2012, 10, 131.	2.3	39
867	Co-prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population-based study with focus on gender differences. <i>BMC Medicine</i> , 2012, 10, 148.	2.3	16
868	Moving towards a population health approach to the primary prevention of common mental disorders. <i>BMC Medicine</i> , 2012, 10, 149.	2.3	183
869	Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. <i>BMC Medicine</i> , 2012, 10, 66.	2.3	479
870	Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. <i>BMC Medicine</i> , 2012, 10, 91.	2.3	81
871	State-related alterations of gene expression in bipolar disorder: a systematic review. <i>Bipolar Disorders</i> , 2012, 14, 684-696.	1.1	38
872	Translating the Rosetta Stone of N-Acetylcysteine. <i>Biological Psychiatry</i> , 2012, 71, 935-936.	0.7	20
873	Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2012, 87, 135-141.	1.0	153
874	Depressive symptoms in first episode schizophrenia spectrum disorder. <i>Schizophrenia Research</i> , 2012, 134, 20-26.	1.1	71
875	Are we missing opportunities for early intervention in bipolar disorder?. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 5-7.	1.4	15
876	Nutrient intakes and the common mental disorders in women. <i>Journal of Affective Disorders</i> , 2012, 141, 79-85.	2.0	121
877	Mania: Diagnosis and Treatment Recommendations. <i>Current Psychiatry Reports</i> , 2012, 14, 676-686.	2.1	13
878	The science and practice of lithium therapy. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 192-211.	1.3	151
879	Minocycline. <i>CNS Drugs</i> , 2012, 26, 391-401.	2.7	117
880	Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice. <i>BMC Psychiatry</i> , 2012, 12, 228.	1.1	20
881	The impact of statins on psychological wellbeing: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2012, 10, 154.	2.3	67
882	Pathways to new drug discovery in neuropsychiatry. <i>BMC Medicine</i> , 2012, 10, 151.	2.3	17

#	ARTICLE	IF	CITATIONS
883	New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidatesâ€”Nrf2 activators and GSK-3 inhibitors. <i>Inflammopharmacology</i> , 2012, 20, 127-150.	1.9	285
884	Complementary medicine, self-help, and lifestyle interventions for Obsessive Compulsive Disorder (OCD) and the OCD spectrum: A systematic review. <i>Journal of Affective Disorders</i> , 2012, 138, 213-221.	2.0	46
885	Increased autoimmune activity against 5-HT: A key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. <i>Journal of Affective Disorders</i> , 2012, 136, 386-392.	2.0	96
886	The use of hormonal contraceptive agents and mood disorders in women. <i>Journal of Affective Disorders</i> , 2012, 140, 92-96.	2.0	35
887	Psychometric properties of a scale to measure investment in the sick role: the Illness Cognitions Scale. <i>Journal of Evaluation in Clinical Practice</i> , 2012, 18, 360-364.	0.9	13
888	Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18â€”month pilot study. <i>Microbial Biotechnology</i> , 2012, 6, 380-388.	0.9	34
889	Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. <i>Acta Psychiatrica Scandinavica</i> , 2012, 125, 303-308.	2.2	78
890	Amygdala and insula volumes prior to illness onset in bipolar disorder: A magnetic resonance imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2012, 201, 34-39.	0.9	46
891	Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. <i>Bipolar Disorders</i> , 2012, 14, 1-21.	1.1	48
892	Impact of sunlight on the age of onset of bipolar disorder. <i>Bipolar Disorders</i> , 2012, 14, 654-663.	1.1	39
893	Depression, diet and exercise. <i>Medical Journal of Australia</i> , 2012, 1, 21-23.	0.8	8
894	Difficult-to-treat depression. <i>Medical Journal of Australia</i> , 2012, 1, 4-5.	0.8	0
895	Treatment of bipolar depression. <i>Medical Journal of Australia</i> , 2012, 1, 32-35.	0.8	2
896	A Consensus Statement for Safety Monitoring Guidelines of Treatments for Major Depressive Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 712-725.	1.3	41
897	The relationship between substance use and posttraumatic stress disorder in a methadone maintenance treatment program. <i>Comprehensive Psychiatry</i> , 2011, 52, 562-566.	1.5	25
898	Paracetamol (acetaminophen) use, fracture and bone mineral density. <i>Bone</i> , 2011, 48, 1277-1281.	1.4	20
899	The Association Between Habitual Diet Quality and the Common Mental Disorders in Community-Dwelling Adults. <i>Psychosomatic Medicine</i> , 2011, 73, 483-490.	1.3	245
900	N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder. <i>Neuroscience Letters</i> , 2011, 499, 149-153.	1.0	75

#	ARTICLE	IF	CITATIONS
901	Area-based socioeconomic status and mood disorders: Cross-sectional evidence from a cohort of randomly selected adult women. <i>Maturitas</i> , 2011, 69, 173-178.	1.0	17
902	An apoptosis panel for nonalcoholic steatohepatitis diagnosis. <i>Journal of Hepatology</i> , 2011, 54, 1224-1229.	1.8	165
903	A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 676-692.	2.5	960
904	Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 769-783.	2.5	131
905	Nutraceuticals in the treatment of Obsessive Compulsive Disorder (OCD): A review of mechanistic and clinical evidence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 887-895.	2.5	50
906	(Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: From antioxidants to kinase inhibitors. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 659-663.	2.5	92
907	Transcriptional Profile of Genes Involved in Oxidative Stress and Antioxidant Defense in a Dietary Murine Model of Steatohepatitis. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 437-445.	2.5	60
908	P.2.a.015 Child abuse and depression severity more than genotype predictive of antidepressant response. <i>European Neuropsychopharmacology</i> , 2011, 21, S362.	0.3	0
909	Should antipsychotics take pole position in mania treatment?. <i>Lancet, The</i> , 2011, 378, 1279-1281.	6.3	11
910	Bipolar disorder supplement needed broader perspective. <i>Medical Journal of Australia</i> , 2011, 194, 326-326.	0.8	0
911	N-acetylcysteine for major depressive episodes in bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , 2011, 33, 374-378.	0.9	99
912	A Prospective Study of Diet Quality and Mental Health in Adolescents. <i>PLoS ONE</i> , 2011, 6, e24805.	1.1	257
913	The Efficacy and Safety of Alprazolam Versus Other Benzodiazepines in the Treatment of Panic Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 647-652.	0.7	24
914	Annual high-dose vitamin D ₃ and mental well-being: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2011, 198, 357-364.	1.7	139
915	Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. <i>Bipolar Disorders</i> , 2011, 13, 87-98.	1.1	155
916	Development of guidelines for caregivers of people with bipolar disorder: a Delphi expert consensus study. <i>Bipolar Disorders</i> , 2011, 13, 556-570.	1.1	42
917	Modeling gene-environment interaction in longitudinal data: Risk for neuroticism due to interaction between maternal care and the Dopamine 4 Receptor gene (DRD4). <i>Australian Journal of Psychology</i> , 2011, 63, 18-25.	1.4	10
918	Meta-analytic review of neurocognition in bipolar II disorder. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 165-174.	2.2	134

#	ARTICLE	IF	CITATIONS
919	Dimensions of improvement in a clinical trial of N-acetyl cysteine for bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2011, 23, 87-88.	1.0	7
920	Bipolar disorder and adiposity: a study using whole body dual energy X-ray absorptiometry scans. <i>Acta Neuropsychiatrica</i> , 2011, 23, 219-223.	1.0	3
921	Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. <i>Microbial Biotechnology</i> , 2011, 5, 100-107.	0.9	34
922	Lower levels of physical activity in childhood associated with adult depression. <i>Journal of Science and Medicine in Sport</i> , 2011, 14, 222-226.	0.6	64
923	N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. <i>Journal of Affective Disorders</i> , 2011, 129, 317-320.	2.0	93
924	Diet quality in bipolar disorder in a population-based sample of women. <i>Journal of Affective Disorders</i> , 2011, 129, 332-337.	2.0	89
925	The association between depressive and anxiety symptoms and bone mineral density in the general population: The HUNT Study. <i>Journal of Affective Disorders</i> , 2011, 131, 164-171.	2.0	44
926	Glutamate cysteine ligase (GCL) and self reported depression: An association study from the HUNT. <i>Journal of Affective Disorders</i> , 2011, 131, 207-213.	2.0	12
927	The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. <i>Journal of Affective Disorders</i> , 2011, 135, 389-394.	2.0	162
928	Venlafaxine modulates depression-induced behaviour and the expression of Bax mRNA and Bcl-xl mRNA in both hippocampus and myocardium. <i>Human Psychopharmacology</i> , 2011, 26, 95-101.	0.7	27
929	Who's left? Symptoms of schizophrenia that predict clinical trial dropout. <i>Human Psychopharmacology</i> , 2011, 26, 609-613.	0.7	7
930	Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 804-817.	2.9	1,007
931	ANZJP this Month. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 907-908.	1.3	0
932	Habitual physical activity and the risk for depressive and anxiety disorders among older men and women. <i>International Psychogeriatrics</i> , 2011, 23, 292-298.	0.6	92
933	Don't Worry, be Active: Positive Affect and Habitual Physical Activity. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 1047-1052.	1.3	68
934	Depolarizing Bipolar Disorder: Both the Illness and Our Views. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 909-910.	1.3	6
935	N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 78-86.	1.4	373
936	An Examination of Risk Factors for Readmission to Acute Adult Mental Health Services Within 28 Days of Discharge in the Australian Setting. <i>Australasian Psychiatry</i> , 2011, 19, 221-225.	0.4	30

#	ARTICLE	IF	CITATIONS
937	Psychosis continuum and neurocognition in bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , 2011, 33, 319-320.	0.9	4
938	Qualitative Methods in Early-Phase Drug Trials. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 909-913.	1.1	29
939	The Use of Statins After a Cardiac Intervention Is Associated With Reduced Risk of Subsequent Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1229-1235.	1.1	82
940	Response to: Retinol-binding Protein 4 Concentrations in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 232.	1.1	0
941	Readmission to an acute psychiatric unit within 28 days of discharge: identifying those at risk. <i>Australian Health Review</i> , 2010, 34, 282.	0.5	31
942	A qualitative evaluation of a regional Early Psychosis Service 3 years after its commencement. <i>Australian Health Review</i> , 2010, 34, 382.	0.5	9
943	Group-based psychosocial intervention for bipolar disorder: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2010, 196, 383-388.	1.7	111
944	Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 97, 293-300.	1.3	15
945	Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. <i>Psychoneuroendocrinology</i> , 2010, 35, 1142-1147.	1.3	106
946	Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. <i>European Journal of Pharmacology</i> , 2010, 649, 224-228.	1.7	54
947	A prospective study of the impact of subthreshold mixed states on the 24-month clinical outcomes of bipolar I disorder or schizoaffective disorder. <i>Journal of Affective Disorders</i> , 2010, 124, 22-28.	2.0	25
948	Characterisation of the prodrome to a first episode of psychotic mania: Results of a retrospective study. <i>Journal of Affective Disorders</i> , 2010, 124, 341-345.	2.0	66
949	Pre-morbid and outcome correlates of first episode mania with psychosis: Is a distinction between schizoaffective and bipolar I disorder valid in the early phase of psychotic disorders?. <i>Journal of Affective Disorders</i> , 2010, 126, 88-95.	2.0	24
950	A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. <i>Journal of Affective Disorders</i> , 2010, 127, 316-320.	2.0	104
951	Enhancing medication adherence in patients with bipolar disorder. <i>Human Psychopharmacology</i> , 2010, 25, 1-16.	0.7	115
952	Prevalence of mood and anxiety disorder in self reported irritable bowel syndrome (IBS). An epidemiological population based study of women. <i>BMC Gastroenterology</i> , 2010, 10, 88.	0.8	96
953	Termination of therapy: what can clinicians do to maximise gains?. <i>Acta Neuropsychiatrica</i> , 2010, 22, 43-45.	1.0	5
954	Pharmacotherapy for co-occurring alcohol and drug disorders in schizophrenia and bipolar disorder: where is the evidence?. <i>Acta Neuropsychiatrica</i> , 2010, 22, 95-97.	1.0	3

#	ARTICLE	IF	CITATIONS
955	Obesity is associated with previous suicide attempts in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2010, 22, 63-67.	1.0	38
956	Validity of the Portuguese version of the Bipolar Depression Rating Scale. <i>Acta Neuropsychiatrica</i> , 2010, 22, 100-101.	1.0	2
957	Mental health services for young people – the challenge of integrating services. <i>Acta Neuropsychiatrica</i> , 2010, 22, 158-160.	1.0	6
958	Detached from attachment: neurobiology and phenomenology have a human face. <i>Acta Neuropsychiatrica</i> , 2010, 22, 202-206.	1.0	7
959	Duloxetine 60 mg/day for the prevention of depressive recurrences: <i>post hoc</i> analyses from a recurrence prevention study. <i>International Journal of Clinical Practice</i> , 2010, 64, 719-726.	0.8	11
960	The validity and internal structure of the Bipolar Depression Rating Scale: data from a clinical trial of N-acetylcysteine as adjunctive therapy in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2010, 22, 237-242.	1.0	10
961	Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2010, 64, 367-371.	1.0	11
962	Pretreatment and outcome correlates of past sexual and physical trauma in 118 bipolar I disorder patients with a first episode of psychotic mania. <i>Bipolar Disorders</i> , 2010, 12, 244-252.	1.1	79
963	Assessing oxidative pathway genes as risk factors for bipolar disorder. <i>Bipolar Disorders</i> , 2010, 12, 550-556.	1.1	36
964	Bipolar disorder: new understandings, emerging treatments. <i>Medical Journal of Australia</i> , 2010, 193, S3-4.	0.8	4
965	The pharmacological treatment of bipolar disorder in primary care. <i>Medical Journal of Australia</i> , 2010, 193, S24-30.	0.8	9
966	The role of psychotherapy in bipolar disorder. <i>Medical Journal of Australia</i> , 2010, 193, S31-5.	0.8	51
967	Adipocyte Apoptosis, a Link between Obesity, Insulin Resistance, and Hepatic Steatosis. <i>Journal of Biological Chemistry</i> , 2010, 285, 3428-3438.	1.6	286
968	Association of Western and Traditional Diets With Depression and Anxiety in Women. <i>American Journal of Psychiatry</i> , 2010, 167, 305-311.	4.0	583
969	Patterns of Alcohol Use and Associated Physical and Lifestyle Characteristics According to New Australian Guidelines. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 946-951.	1.3	15
970	Association of high-sensitivity C-reactive protein with <i>de novo</i> major depression. <i>British Journal of Psychiatry</i> , 2010, 197, 372-377.	1.7	281
971	Associations Between Diet Quality and Depressed Mood in Adolescents: Results from the Australian Healthy Neighbourhoods Study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 435-442.	1.3	185
972	Evidence and implications for early intervention in bipolar disorder. <i>Journal of Mental Health</i> , 2010, 19, 113-126.	1.0	110

#	ARTICLE	IF	CITATIONS
973	The Prevalence of Mood and Anxiety Disorders in Australian Women. <i>Australasian Psychiatry</i> , 2010, 18, 250-255.	0.4	48
974	Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Journal of Lipid Research</i> , 2010, 51, 3046-3054.	2.0	237
975	Restless Leg Syndrome Associated with Olanzapine: A Case Series. <i>Current Drug Safety</i> , 2010, 5, 129-131.	0.3	25
976	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 81-109.	1.3	322
977	Clinical Implications of the Cytokine Hypothesis of Depression: The Association between Use of Statins and Aspirin and the Risk of Major Depression. <i>Psychotherapy and Psychosomatics</i> , 2010, 79, 323-325.	4.0	82
978	Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. <i>Schizophrenia Research</i> , 2010, 119, 1-10.	1.1	97
979	The Impact of Smoking on Clinical Outcomes After First Episode Psychosis: Longer-Term Outcome Findings From the EPPIC 800 Follow-Up Study. <i>Journal of Dual Diagnosis</i> , 2010, 6, 212-234.	0.7	9
980	A prospective study of the impact of smoking on outcomes in bipolar and schizoaffective disorder. <i>Comprehensive Psychiatry</i> , 2010, 51, 504-509.	1.5	48
981	Oxidative pathways as a drug target for the treatment of autism. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1301-1310.	1.5	35
982	The utility of the Mood Disorders Questionnaire as a screening tool in a methadone maintenance treatment program. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 150-153.	1.2	4
983	Selective Estrogen Receptor Modulator Treatment in Postmenopausal Women with Schizophrenia.. , 2010, , P1-203-P1-203.		0
984	From neuroprogression to neuroprotection: implications for clinical care. <i>Medical Journal of Australia</i> , 2010, 193, S36-40.	0.8	68
985	Reliability of the Mood Disorder Questionnaire: Comparison with the Structured Clinical Interview for the DSM-IV-TR in a Population Sample. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 526-530.	1.3	36
986	Neuroprogression: pathways to progressive brain changes in bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 441.	1.0	161
987	Depression and Bone Metabolism. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 16-25.	4.0	51
988	The Elephant on the Couch: Side-Effects of Psychotherapy. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 787-794.	1.3	132
989	Description and Qualitative Evaluation of Jigsaw, an Integrated Young Persons's™ Mental Health Program. <i>Australasian Psychiatry</i> , 2009, 17, 480-483.	0.4	8
990	Is Lithium in a Class of Its Own? A Brief Profile of Its Clinical Use. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 1096-1104.	1.3	57

#	ARTICLE	IF	CITATIONS
991	Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. <i>Journal of Psychopharmacology</i> , 2009, 23, 985-987.	2.0	30
992	Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation. <i>Neurobiology of Disease</i> , 2009, 33, 354-357.	2.1	107
993	Clinical practice recommendations for depression. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 8-26.	2.2	82
994	Clinical practice recommendations for bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 27-46.	2.2	110
995	Differences between subjective and objective assessments of the utility of Electroconvulsive therapy in patients with bipolar and unipolar depression. <i>Journal of Affective Disorders</i> , 2009, 112, 212-218.	2.0	31
996	Early intervention in bipolar disorders: Clinical, biochemical and neuroimaging imperatives. <i>Journal of Affective Disorders</i> , 2009, 114, 1-13.	2.0	75
997	Lifetime psychiatric disorders and body composition: A population-based study. <i>Journal of Affective Disorders</i> , 2009, 118, 173-179.	2.0	56
998	Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. <i>Journal of Affective Disorders</i> , 2009, 119, 22-27.	2.0	63
999	Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. <i>Human Psychopharmacology</i> , 2009, 24, 233-238.	0.7	60
1000	A critical update on psychological interventions for bipolar disorders. <i>Current Psychiatry Reports</i> , 2009, 11, 494-502.	2.1	56
1001	“Mind and Body™: a lifestyle programme for people on antipsychotic medication. <i>Journal of Evaluation in Clinical Practice</i> , 2009, 15, 276-280.	0.9	3
1002	The therapeutic alliance: is it necessary or sufficient to engender positive outcomes?. <i>Acta Neuropsychiatrica</i> , 2009, 21, 95-98.	1.0	23
1003	Suicidality “the challenge for public mental health services. <i>Acta Neuropsychiatrica</i> , 2009, 21, 41-43.	1.0	1
1004	Trauma and psychosis: some aspects of a complex relationship. <i>Acta Neuropsychiatrica</i> , 2009, 21, 148-150.	1.0	3
1005	Duration of untreated psychosis: What are we talking about?. <i>Acta Neuropsychiatrica</i> , 2009, 21, 106-108.	1.0	4
1006	Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial. <i>Acta Neuropsychiatrica</i> , 2009, 21, 285-291.	1.0	13
1007	The impact of age at onset of bipolar I disorder on functioning and clinical presentation. <i>Acta Neuropsychiatrica</i> , 2009, 21, 191-196.	1.0	22
1008	The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. <i>Acta Neuropsychiatrica</i> , 2009, 21, 272-274.	1.0	29

#	ARTICLE	IF	CITATIONS
1009	Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial. <i>Acta Neuropsychiatrica</i> , 2009, 21, 239-245.	1.0	9
1010	Psychosocial interventions for bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2009, 21, 275-284.	1.0	19
1011	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. <i>Bipolar Disorders</i> , 2009, 11, 225-255.	1.1	545
1012	Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. <i>Bipolar Disorders</i> , 2009, 11, 55-76.	1.1	43
1013	The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. <i>Bipolar Disorders</i> , 2009, 11, 453-473.	1.1	401
1014	The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. <i>Bipolar Disorders</i> , 2009, 11, 559-595.	1.1	159
1015	Client-reported reasons for non-engagement in drug and alcohol treatment. <i>Drug and Alcohol Review</i> , 2009, 28, 372-378.	1.1	27
1016	Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. <i>Behavioural Brain Research</i> , 2009, 198, 258-262.	1.2	63
1017	The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1366-1371.	2.5	139
1018	Are illness perceptions about coronary artery disease predictive of depression and quality of life outcomes?. <i>Journal of Psychosomatic Research</i> , 2009, 66, 211-220.	1.2	98
1019	Levels of neuregulin 1 and 3 proteins in Brodmann's area 46 from subjects with schizophrenia and bipolar disorder. <i>Neuroscience Letters</i> , 2009, 466, 27-29.	1.0	11
1020	Clinical implications of a staging model for bipolar disorders. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 957-966.	1.4	214
1021	A Pilot Study of at-risk Criteria for Bipolar Disorders in Help Seeking Adolescents and Young Adults. <i>European Psychiatry</i> , 2009, 24, .	0.1	0
1022	Vitamin D: is it relevant to psychiatry?. <i>Acta Neuropsychiatrica</i> , 2009, 21, 205-206.	1.0	9
1023	Writing letters to patients. <i>Acta Neuropsychiatrica</i> , 2009, 21, 314-316.	1.0	3
1024	Hepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease. <i>Journal of Biological Chemistry</i> , 2009, 284, 5637-5644.	1.6	359
1025	Serum Retinol-binding Protein 4 Levels in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 985-989.	1.1	70
1026	Nail-Biting Stuff? The Effect of N-acetyl Cysteine on Nail-Biting. <i>CNS Spectrums</i> , 2009, 14, 357-360.	0.7	53

#	ARTICLE	IF	CITATIONS
1027	Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1416-1423.	1.1	108
1028	Cognitive-Personality Style as Vulnerability to Depression in Patients With Coronary Artery Disease: Roles of Sociotropy and Autonomy. <i>Psychosomatic Medicine</i> , 2009, 71, 63-69.	1.3	16
1029	A Role for Glutathione in the Pathophysiology of Bipolar Disorder and Schizophrenia? Animal Models and Relevance to Clinical Practice. <i>Current Medicinal Chemistry</i> , 2009, 16, 2965-2976.	1.2	81
1030	Abnormalities in Osteoclastogenesis and Decreased Tumorigenesis in Mice Deficient for Ovarian Cancer G Protein-Coupled Receptor 1. <i>PLoS ONE</i> , 2009, 4, e5705.	1.1	77
1031	The Management of Individuals with Bipolar Disorder. <i>Drugs</i> , 2009, 69, 2063-2101.	4.9	46
1032	Olanzapine/Fluoxetine Combination for the Treatment of Mixed Depression in Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1424-1431.	1.1	55
1033	Intervention in Individuals at Ultra-High Risk for Psychosis. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1206-1212.	1.1	258
1034	Sleep and depression - theory and practice. <i>Australian Family Physician</i> , 2009, 38, 302-4.	0.5	29
1035	Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. <i>Annals of the Academy of Medicine, Singapore</i> , 2009, 38, 396-6.	0.2	53
1036	Effect of Chronic N-Acetyl Cysteine Administration on Oxidative Status in the Presence and Absence of Induced Oxidative Stress in Rat Striatum. <i>Neurochemical Research</i> , 2008, 33, 508-517.	1.6	72
1037	The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. <i>Hepatology</i> , 2008, 47, 1495-1503.	3.6	242
1038	Major psychoses with mixed psychotic and mood symptoms: are mixed psychoses associated with different neurobiological markers?. <i>Acta Psychiatrica Scandinavica</i> , 2008, 118, 172-187.	2.2	53
1039	Genetically guided prescribing: Hope or hype?. <i>Acta Neuropsychiatrica</i> , 2008, 20, 50-51.	1.0	2
1040	To E or not to E? The case for electronic health records. <i>Acta Neuropsychiatrica</i> , 2008, 20, 104-106.	1.0	4
1041	Oxidative stress may be a common mechanism linking major depression and osteoporosis. <i>Acta Neuropsychiatrica</i> , 2008, 20, 112-116.	1.0	23
1042	When illness does not get better: do we need a palliative psychiatry?. <i>Acta Neuropsychiatrica</i> , 2008, 20, 165-166.	1.0	10
1043	Brain-derived neurotrophic factor: a modifiable common mediator in both the pathophysiology of psychiatric illness and in successful pharmacological treatments. <i>Acta Neuropsychiatrica</i> , 2008, 20, 223-225.	1.0	1
1044	Rhythm and blues. <i>Acta Neuropsychiatrica</i> , 2008, 20, 319-320.	1.0	1

#	ARTICLE	IF	CITATIONS
1045	Small shifts in diurnal rhythms are associated with an increase in suicide: The effect of daylight saving. <i>Sleep and Biological Rhythms</i> , 2008, 6, 22-25.	0.5	43
1046	Diagnostic guidelines for bipolar disorder: a summary of the <i>International Society for Bipolar Disorders</i> Diagnostic Guidelines Task Force Report. <i>Bipolar Disorders</i> , 2008, 10, 117-128.	1.1	86
1047	Pure and mixed manic subtypes: a review of diagnostic classification and validation. <i>Bipolar Disorders</i> , 2008, 10, 131-143.	1.1	55
1048	The proximal prodrome to first episode mania – a new target for early intervention. <i>Bipolar Disorders</i> , 2008, 10, 555-565.	1.1	90
1049	A functional MRI study of Theory of Mind in euthymic bipolar disorder patients. <i>Bipolar Disorders</i> , 2008, 10, 943-956.	1.1	76
1050	The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. <i>Journal of Evaluation in Clinical Practice</i> , 2008, 14, 979-983.	0.9	194
1051	A descriptive interview with 64 patients discharged from an acute <i>psychiatric</i> inpatient service. <i>Journal of Evaluation in Clinical Practice</i> , 2008, 14, 990-995.	0.9	0
1052	The empirical redefinition of the psychometric criteria for remission in bipolar disorder. <i>Journal of Affective Disorders</i> , 2008, 106, 153-158.	2.0	78
1053	Leptin in depressed women: Cross-sectional and longitudinal data from an epidemiologic study. <i>Journal of Affective Disorders</i> , 2008, 107, 221-225.	2.0	89
1054	The Bipolar Comprehensive Outcomes Study (BCOS): Baseline findings of an Australian cohort study. <i>Journal of Affective Disorders</i> , 2008, 107, 135-144.	2.0	12
1055	Depressive disorders and bone mineral density in a community based sample of premenopausal women. <i>Journal of Affective Disorders</i> , 2008, 107, S96-S97.	2.0	0
1056	Guidelines for assessment and monitoring of treatment. <i>Journal of Affective Disorders</i> , 2008, 107, S48.	2.0	0
1057	Going up in smoke: Tobacco smoking is associated with worse treatment outcomes in mania. <i>Journal of Affective Disorders</i> , 2008, 110, 126-134.	2.0	77
1058	Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 851-76.	1.0	821
1059	PHP24 USE OF THE AMCP FORMAT IN THE U.S.: A NATIONAL SURVEY OF HEALTH PLANS. <i>Value in Health</i> , 2008, 11, A369.	0.1	1
1060	N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia – A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2008, 64, 361-368.	0.7	489
1061	N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder – A Double-Blind Randomized Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2008, 64, 468-475.	0.7	452
1062	Is this D Vitamin to Worry About? Vitamin D Insufficiency in an Inpatient Sample. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008, 42, 874-878.	1.3	43

#	ARTICLE	IF	CITATIONS
1063	Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. <i>Neuroscience Letters</i> , 2008, 433, 270-273.	1.0	34
1064	Decreased serum neurotrophin 3 in chronically medicated schizophrenic males. <i>Neuroscience Letters</i> , 2008, 440, 197-201.	1.0	22
1065	Serum levels of brain-derived neurotrophic factor in schizophrenia on a hypocaloric diet. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1595-1598.	2.5	32
1066	Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1677-1681.	2.5	188
1067	Glutathione: a novel treatment target in psychiatry. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 346-351.	4.0	166
1068	N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1955-1962.	1.4	335
1069	Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2008, 33, 2187-2199.	2.8	321
1070	Dual Action? Combining Venlafaxine and Mirtazapine in the Treatment of Depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008, 42, 346-349.	1.3	20
1071	Tobacco smoking as a risk factor for major depressive disorder: population-based study. <i>British Journal of Psychiatry</i> , 2008, 193, 322-326.	1.7	190
1072	Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1299-1306.	1.4	19
1073	Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. <i>International Clinical Psychopharmacology</i> , 2008, 23, 84-87.	0.9	97
1074	Illness Beliefs About Heart Disease and Adherence to Secondary Prevention Regimens. <i>Psychosomatic Medicine</i> , 2008, 70, 942-948.	1.3	48
1075	Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. <i>Revista Brasileira De Psiquiatria</i> , 2008, 30, 337-340.	0.9	28
1076	Acute management of bipolar disorders. <i>Australian Prescriber</i> , 2008, 31, 73-76.	0.5	2
1077	Bipolar disorders. <i>Australian Prescriber</i> , 2008, 31, 115-118.	0.5	1
1078	Silencing of Stearoyl-CoA Desaturase Inhibits Proliferation and Induces Apoptosis in Human Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2008, 103, S146.	0.2	1
1079	Increased Soluble Fas and Fas Ligand Levels in Patients with Nonalcoholic Steatohepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, S122.	0.2	0
1080	The Ski oncoprotein regulates Hematopoietic Stem Cell Fitness and Functions as a Corepressor for Cfi1. <i>Blood</i> , 2008, 112, 1403-1403.	0.6	0

#	ARTICLE	IF	CITATIONS
1081	Plasma Lysophosphatidylcholine Levels: Potential Biomarkers for Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2696-2701.	0.8	174
1082	Pilot of group intervention for bipolar disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 279-284.	1.2	22
1083	Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs. <i>Evidence-Based Mental Health</i> , 2007, 10, 17-17.	2.2	2
1084	A Survey of Combination Antidepressant Use in Australia. <i>Australasian Psychiatry</i> , 2007, 15, 26-29.	0.4	30
1085	Ovarian Cancer G Protein Coupled Receptor 1, a New Metastasis Suppressor Gene in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1313-1327.	3.0	81
1086	DNA damage in rats after treatment with methylphenidate. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1282-1288.	2.5	64
1087	Comorbid depression and health-related quality of life in patients with coronary artery disease. <i>Journal of Psychosomatic Research</i> , 2007, 62, 401-410.	1.2	82
1088	Depression and bone mineral density in a community sample of men: Geelong Osteoporosis Study. <i>The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender</i> , 2007, 4, 292-297.	0.3	6
1089	Vitamin D deficiency may play a role in depression. <i>Medical Hypotheses</i> , 2007, 69, 1316-1319.	0.8	164
1090	Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. <i>Neuroscience Letters</i> , 2007, 420, 45-48.	1.0	135
1091	Self-Reported Depression and Cardiovascular Risk Factors in a Community Sample of Women. <i>Psychosomatics</i> , 2007, 48, 54-59.	2.5	20
1092	Monitoring the Safe Use of Clozapine. <i>CNS Drugs</i> , 2007, 21, 117-127.	2.7	50
1093	CNS 14-3-3 σ : Changes with sex but not psychiatric diagnoses or psychotropic drug treatment. <i>Schizophrenia Research</i> , 2007, 93, 51-57.	1.1	9
1094	Early intervention in bipolar disorders: opportunities and pitfalls. <i>Medical Journal of Australia</i> , 2007, 187, S11-4.	0.8	68
1095	Effects of a walking program in the psychiatric in-patient treatment setting: a cohort study. <i>Health Promotion Journal of Australia</i> , 2007, 18, 39-42.	0.6	9
1096	The validity of the 21-item version of the Depression Anxiety Stress Scales as a routine clinical outcome measure. <i>Acta Neuropsychiatrica</i> , 2007, 19, 304-310.	1.0	263
1097	Neuroprotection in emerging psychotic disorders. <i>Microbial Biotechnology</i> , 2007, 1, 114-127.	0.9	45
1098	Setting the stage: from prodrome to treatment resistance in bipolar disorder. <i>Bipolar Disorders</i> , 2007, 9, 671-678.	1.1	204

#	ARTICLE	IF	CITATIONS
1099	The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. <i>Bipolar Disorders</i> , 2007, 9, 571-579.	1.1	126
1100	Early intervention in bipolar disorders. <i>Acta Neuropsychiatrica</i> , 2007, 19, 68-69.	1.0	8
1101	The place of placebo? The ethics of placebo-controlled trials in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2007, 19, 74-75.	1.0	4
1102	Should we be targeting smoking as a routine intervention?. <i>Acta Neuropsychiatrica</i> , 2007, 19, 131-132.	1.0	31
1103	Should we be targeting exercise as a routine mental health intervention?. <i>Acta Neuropsychiatrica</i> , 2007, 19, 217-218.	1.0	15
1104	Oxidative biology: new intervention opportunities in psychiatry. <i>Acta Neuropsychiatrica</i> , 2007, 19, 259-260.	1.0	10
1105	Net-effect? Online psychological interventions. <i>Acta Neuropsychiatrica</i> , 2007, 19, 386-388.	1.0	15
1106	Does dopamine dysfunction drive depression?. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 116-124.	2.2	71
1107	Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 41-49.	2.2	317
1108	Validity of the Hospital Anxiety and Depression Scale and Patient Health Questionnaire-9 to screen for depression in patients with coronary artery disease. <i>General Hospital Psychiatry</i> , 2007, 29, 417-424.	1.2	215
1109	The effects of physical activity in the acute treatment of bipolar disorder: A pilot study. <i>Journal of Affective Disorders</i> , 2007, 101, 259-262.	2.0	105
1110	History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. <i>Journal of Affective Disorders</i> , 2007, 103, 181-186.	2.0	194
1111	The potential utility of a staging model as a course specifier: A bipolar disorder perspective. <i>Journal of Affective Disorders</i> , 2007, 100, 279-281.	2.0	140
1112	The role of lamotrigine in the management of bipolar disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 463-74.	1.0	22
1113	FC3B THE ORYGEN FIRST EPISODE MANIA STUDY: AN 8 WEEKS COMPARISON OF CHLORPROMAZINE AND OLANZAPINE IN COMBINATION WITH LITHIUM.. <i>Schizophrenia Research</i> , 2006, 86, S37.	1.1	0
1114	FC3C THE PRODROME TO FIRST EPISODE PSYCHOTIC MANIA: RESULTS OF A RETROSPECTIVE STUDY. <i>Schizophrenia Research</i> , 2006, 86, S37.	1.1	2
1115	O274 THE DEVELOPMENTAL CONSIDERATIONS FOR PSYCHOLOGICAL TREATMENT OF FIRST EPISODE BIPOLAR DISORDER. <i>Schizophrenia Research</i> , 2006, 86, S141.	1.1	4
1116	Time course of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. <i>Acta Neuropsychiatrica</i> , 2006, 18, 248-248.	1.0	0

#	ARTICLE	IF	CITATIONS
1117	05-03 Disease burden of bipolar and schizoaffective disorder in an Australian cohort. <i>Acta Neuropsychiatrica</i> , 2006, 18, 325-325.	1.0	0
1118	Pilot study of physical activity in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2006, 18, 300-301.	1.0	0
1119	The impact of age at onset of bipolar 1 disorder on functioning and clinical presentation. <i>Acta Neuropsychiatrica</i> , 2006, 18, 242-243.	1.0	1
1120	Self-reported depression and reduced bone mineral density in a community sample of men: Geelong Osteoporosis Study. <i>Acta Neuropsychiatrica</i> , 2006, 18, 293-294.	1.0	0
1121	Diagnosing bipolar disorder: how can we do it better?. <i>Medical Journal of Australia</i> , 2006, 184, 459-462.	0.8	36
1122	Clozapine and cardiotoxicity: echocardiography findings from Barwon Health. <i>Acta Neuropsychiatrica</i> , 2006, 18, 249-250.	1.0	0
1123	SSRI use and bone mineral density in women with a history of depression: Geelong Osteoporosis Study. <i>Acta Neuropsychiatrica</i> , 2006, 18, 311-312.	1.0	1
1124	The effect of macroeconomic variables on suicide. <i>Psychological Medicine</i> , 2006, 36, 181-189.	2.7	92
1125	The utility of the Clinical Global Impression Scale in the clinical setting. <i>Acta Neuropsychiatrica</i> , 2006, 18, 301-301.	1.0	4
1126	Symptomatic and functional outcome 12 months after a first episode of psychotic mania: barriers to recovery in a catchment area sample. <i>Bipolar Disorders</i> , 2006, 8, 221-231.	1.1	110
1127	Depression and pain: an overview. <i>Acta Neuropsychiatrica</i> , 2006, 18, 79-87.	1.0	61
1128	Seasonal influences on first-episode admission in affective and non-affective psychosis. <i>Acta Neuropsychiatrica</i> , 2006, 18, 154-161.	1.0	11
1129	Do ambient electromagnetic fields affect behaviour? A demonstration of the relationship between geomagnetic storm activity and suicide. <i>Bioelectromagnetics</i> , 2006, 27, 151-155.	0.9	46
1130	The Safety of Medications for the Treatment of Bipolar Disorder During Pregnancy and the Puerperium. <i>Current Drug Safety</i> , 2006, 1, 25-33.	0.3	18
1131	A Clinical Monitoring System for Clozapine. <i>Australasian Psychiatry</i> , 2006, 14, 156-168.	0.4	15
1132	Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression. <i>Evidence-Based Mental Health</i> , 2006, 9, 42-42.	2.2	1
1133	Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis In vivo. <i>Cancer Research</i> , 2006, 66, 7983-7990.	0.4	132
1134	Pharmacological Treatment in the Early Phase of Bipolar Disorders: What Stage are we at?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 199-207.	1.3	37

#	ARTICLE	IF	CITATIONS
1135	Health-related quality of life and functioning in bipolar disorder: the impact of pharmacotherapy. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 509-523.	0.7	3
1136	Combination pharmacotherapy in unipolar depression. Expert Review of Neurotherapeutics, 2006, 6, 1049-1060.	1.4	10
1137	Depression and mania in mixed states. American Journal of Psychiatry, 2006, 163, 1160.	4.0	1
1138	The Clinical Global Impressions Scale Modified for Substance Use (CGI-SU) in patients with bipolar disorder. Acta Neuropsychiatrica, 2006, 18, 278-279.	1.0	0
1139	Platelet Glutamate Receptors as a Window into Psychiatric Disorders. , 2005, , 233-241.		2
1140	Depression and bone mineral density in a community sample of perimenopausal women: Geelong Osteoporosis Study. Menopause, 2005, 12, 88-91.	0.8	66
1141	Bipolar II disorder: a review. Bipolar Disorders, 2005, 7, 11-21.	1.1	103
1142	Australasian commentary on CANMAT guidelines for treatment of bipolar disorder. Bipolar Disorders, 2005, 7, 83-86.	1.1	2
1143	Executive functioning and theory of mind in euthymic bipolar disorder. Bipolar Disorders, 2005, 7, 43-52.	1.1	128
1144	The management of bipolar disorder in primary care: A review of existing and emerging therapies. Psychiatry and Clinical Neurosciences, 2005, 59, 229-239.	1.0	12
1145	'Bipolar missed states': the diagnosis and clinical salience of bipolar mixed states. Australian and New Zealand Journal of Psychiatry, 2005, 39, 215-221.	1.3	11
1146	Mood stabilizers: a labile label. Acta Psychiatrica Scandinavica, 2005, 111, 5-6.	2.2	6
1147	Atypical mood stabilizers: a 'typical' role for atypical antipsychotics. Acta Psychiatrica Scandinavica, 2005, 111, 29-38.	2.2	25
1148	To combine or not to combine? A literature review of antidepressant combination therapy. Journal of Affective Disorders, 2005, 89, 1-11.	2.0	107
1149	Antidepressants and adolescents: the bipolar confound?. Human Psychopharmacology, 2005, 20, 1-2.	0.7	8
1150	Antidepressants and the placebo response. Human Psychopharmacology, 2005, 20, 305-307.	0.7	8
1151	KiSS1 Suppresses Metastasis in Human Ovarian Cancer via Inhibition of Protein Kinase C Alpha. Clinical and Experimental Metastasis, 2005, 22, 369-376.	1.7	114
1152	The relationship between depression and cardiovascular disease. International Journal of Psychiatry in Clinical Practice, 2005, 9, 157-167.	1.2	22

#	ARTICLE	IF	CITATIONS
1153	Clinical Characteristics and Management of Bipolar Disorder in Women across the Life Span. <i>Women's Health</i> , 2005, 1, 421-428.	0.7	1
1154	Acute Delirium in the Setting of Primary Hypothyroidism: The Role of Thyroid Hormone Replacement Therapy. <i>Thyroid</i> , 2005, 15, 1099-1101.	2.4	21
1155	A review of clozapine safety. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 731-744.	1.0	89
1156	â€˜Bipolar Missed Statesâ€™™: The Diagnosis and Clinical Salience of Bipolar Mixed States. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005, 39, 215-221.	1.3	44
1157	Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression?. <i>Medical Hypotheses</i> , 2005, 65, 39-43.	0.8	61
1158	Efficacy of Atypical Antipsychotics in Bipolar Disorder. <i>Drugs</i> , 2005, 65, 257-269.	4.9	42
1159	Diagnosis and management of patients with bipolar disorder in primary care. <i>British Journal of General Practice</i> , 2005, 55, 662-4.	0.7	4
1160	The pharmacology of bipolar disorder during pregnancy and breastfeeding. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 221-229.	1.0	20
1161	Review: rapid cycling bipolar disorder associated with female gender and bipolar type II subgroup. <i>Evidence-Based Mental Health</i> , 2004, 7, 91-91.	2.2	6
1162	Dietary Omega-3 Fatty Acids and Depression in a Community Sample. <i>Nutritional Neuroscience</i> , 2004, 7, 101-106.	1.5	63
1163	A collaborative approach to the treatment alliance in bipolar disorder. <i>Bipolar Disorders</i> , 2004, 6, 504-518.	1.1	150
1164	Emergency department mental health triage scales improve outcomes. <i>Journal of Evaluation in Clinical Practice</i> , 2004, 10, 57-62.	0.9	41
1165	An audit of clinical outcomes and client and referrer satisfaction with a Mood and Anxiety Disorders Unit. <i>Journal of Evaluation in Clinical Practice</i> , 2004, 10, 549-552.	0.9	6
1166	Scale matters: the need for a Bipolar Depression Rating Scale (BDRS). <i>Acta Psychiatrica Scandinavica</i> , 2004, 110, 39-45.	2.2	51
1167	Predictors of antidepressant response: A selective review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004, 8, 91-100.	1.2	28
1168	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part III: Maintenance Treatment. <i>World Journal of Biological Psychiatry</i> , 2004, 5, 120-135.	1.3	124
1169	Treatment of bipolar mania with atypical antipsychotics. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, S17-S25.	1.4	21
1170	A pilot randomized, double-blind, placebo-controlled study of granisetron in the treatment of sexual dysfunction in women associated with antidepressant use. <i>International Clinical Psychopharmacology</i> , 2004, 19, 161-164.	0.9	16

#	ARTICLE	IF	CITATIONS
1171	Clotiapine for acute psychotic illnesses. The Cochrane Library, 2004, , CD002304.	1.5	21
1172	The pharmacology of bipolar disorder during pregnancy and breastfeeding. Expert Opinion on Drug Safety, 2004, 3, 221-9.	1.0	9
1173	Mood Stabilizers and Treatment Adherence in Bipolar Disorder: Addressing Adverse Events. Annals of Clinical Psychiatry, 2003, 15, 217-224.	0.6	18
1174	Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial. Human Psychopharmacology, 2003, 18, 271-275.	0.7	17
1175	Pharmacological management of aggression and violence. Human Psychopharmacology, 2003, 18, 423-436.	0.7	19
1176	Trichotillomania: response to lithium in a person with comorbid bipolar disorder. Human Psychopharmacology, 2003, 18, 576-577.	0.7	12
1177	American Psychiatric Association practice guidelines for the treatment of psychiatric disorders: Compendium 2002. Australian and New Zealand Journal of Psychiatry, 2003, 37, 499-499.	1.3	0
1178	The evolution of clinical audit as a tool for quality improvement. Journal of Evaluation in Clinical Practice, 2003, 9, 251-257.	0.9	25
1179	Mood disorders: mechanisms and pathophysiology. Acta Neuropsychiatrica, 2003, 15, 307-308.	1.0	1
1180	The platelet window: examining receptor regulated second messenger processes in psychosis and depression. Acta Neuropsychiatrica, 2003, 15, 309-315.	1.0	1
1181	Routine outcome measurement by mental health-care providers. Lancet, The, 2003, 361, 1137-1138.	6.3	7
1182	Routine outcome measurement by mental health-care providers. Lancet, The, 2003, 361, 1137.	6.3	15
1183	Effects of electroconvulsive therapy on regional cerebral blood flow measured by 99mtechnetium HMPAO SPECT. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 15-19.	2.5	33
1184	Duloxetine: a review. Expert Review of Neurotherapeutics, 2003, 3, 447-451.	1.4	1
1185	Recent developments in the treatment of bipolar disorders. Expert Opinion on Investigational Drugs, 2003, 12, 1621-1632.	1.9	10
1186	A Double-Blind, Randomized, Placebo-Controlled Trial of Augmentation With Lamotrigine or Placebo in Patients Concomitantly Treated With Fluoxetine for Resistant Major Depressive Episodes. Journal of Clinical Psychiatry, 2003, 64, 403-407.	1.1	137
1187	Predictive Testing for Huntington's Disease: How Does it Impact on Cognitive Performance?. South African Journal of Psychology, 2002, 32, 39-47.	1.0	0
1188	Improving competence in emergency mental health triage. International Emergency Nursing, 2002, 10, 155-162.	0.7	40

#	ARTICLE	IF	CITATIONS
1189	Serological observations in patients suffering from acute manic episodes. <i>Human Psychopharmacology</i> , 2002, 17, 175-179.	0.7	87
1190	Pharmacotherapy of bipolar disorder: the role of atypical antipsychotics and experimental strategies. <i>Human Psychopharmacology</i> , 2002, 17, 407-412.	0.7	10
1191	Barriers to treatment among members of a mental health advocacy group in South Africa. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2002, 37, 483-487.	1.6	26
1192	Loss of the SKI proto-oncogene in individuals affected with 1p36 deletion syndrome is predicted by strain-dependent defects in <i>Ski</i> ^{-/-} mice. <i>Nature Genetics</i> , 2002, 30, 106-109.	9.4	138
1193	Blunted adenosine A2a receptor function in platelets in patients with major depression. <i>European Neuropsychopharmacology</i> , 2001, 11, 183-186.	0.3	35
1194	The prolactin response to sulpiride in major depression: the role of the D2 receptor in depression. <i>European Neuropsychopharmacology</i> , 2001, 11, 215-220.	0.3	18
1195	Emerging Options in the Treatment of Bipolar Disorders. <i>Drugs</i> , 2001, 61, 1407-1414.	4.9	30
1196	Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. <i>International Clinical Psychopharmacology</i> , 2001, 16, 275-278.	0.9	34
1197	Platelet Glutamate Receptor Supersensitivity in Major Depressive Disorder. <i>Clinical Neuropharmacology</i> , 2001, 24, 129-132.	0.2	54
1198	Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. <i>International Clinical Psychopharmacology</i> , 2001, 16, 87-92.	0.9	89
1199	Value and effectiveness of consumer advocacy groups: A survey of the anxiety disorders support group in South Africa. <i>Depression and Anxiety</i> , 2001, 13, 105-107.	2.0	16
1200	The platelet as a peripheral marker in psychiatric illness. <i>Human Psychopharmacology</i> , 2001, 16, 229-236.	0.7	59
1201	Personality factors, stress and immunity. <i>Stress and Health</i> , 2001, 17, 25-40.	1.4	15
1202	Clotiapine for acute psychotic illnesses. , 2001, , CD002304.		5
1203	Neuroleptic malignant syndrome: Possible induction by olanzapine in a case with relapsing catatonia. <i>International Journal of Psychiatry in Clinical Practice</i> , 2001, 5, 211-213.	1.2	3
1204	Selective serotonin reuptake inhibitors in mixed anxiety-depression. <i>International Clinical Psychopharmacology</i> , 2000, 15, S41-S45.	0.9	12
1205	Serotonergic targets in the treatment of antidepressant induced sexual dysfunction: a pilot study of granisetron and sumatriptan. <i>International Clinical Psychopharmacology</i> , 2000, 15, 291-295.	0.9	15
1206	Changes in the platelet intracellular calcium response to serotonin in patients with major depression treated with electroconvulsive therapy: state or trait marker status. <i>International Clinical Psychopharmacology</i> , 2000, 15, 93-98.	0.9	24

#	ARTICLE	IF	CITATIONS
1207	Platelet Supersensitivity to Thrombin Stimulation in Depression: A Possible Mechanism for the Association with Cardiovascular Mortality. <i>Clinical Neuropharmacology</i> , 2000, 23, 182-185.	0.2	23
1208	Lamotrigine Compared with Lithium in Mania: A Double-Blind Randomized Controlled Trial. <i>Annals of Clinical Psychiatry</i> , 2000, 12, 5-10.	0.6	76
1209	Depression therapy: Future prospects. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 281-286.	1.2	0
1210	Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter. <i>Circulation</i> , 2000, 102, 2385-2390.	1.6	425
1211	The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. <i>Life Sciences</i> , 2000, 66, 2427-2432.	2.0	52
1212	Pharmacotherapy of mania: A review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 171-193.	1.2	11
1213	The role of genetics in suicide and the link with major depression and alcoholism. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 275-280.	1.2	0
1214	The Specificity of Platelet Glutamate Receptor Supersensitivity in Psychotic Disorders. <i>Life Sciences</i> , 2000, 66, 2427-2432.	2.0	13
1215	Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. <i>Annals of Clinical Psychiatry</i> , 2000, 12, 5-10.	0.6	54
1216	Risperidone compared to haloperidol in cannabis-induced psychotic disorder: A double blind randomized controlled trial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 139-142.	1.2	14
1217	Evidence-based psychiatric practice: doctrine or trap?. <i>Journal of Evaluation in Clinical Practice</i> , 1999, 5, 149-152.	0.9	9
1218	Effects of Enforcement of Youth Access Laws on Smoking Prevalence. <i>American Journal of Community Psychology</i> , 1999, 27, 143-160.	1.2	108
1219	Ondansetron inhibits seizure activity with electroconvulsive therapy: a case report. , 1999, 14, 213-213.		0
1220	Relationship between serotonin and the Temperament and Character Inventory. <i>Psychiatry Research</i> , 1999, 89, 29-37.	1.7	105
1221	The platelet intracellular calcium response to serotonin and thrombin in patients with panic disorder. <i>European Neuropsychopharmacology</i> , 1999, 9, 107-110.	0.3	7
1222	Lamotrigine and the treatment of mania in bipolar disorder. <i>European Neuropsychopharmacology</i> , 1999, 9, S119-S123.	0.3	48
1223	Augmented platelet calcium uptake in response to serotonin stimulation in patients with major depression measured using Mn ²⁺ influx and ⁴⁵ Ca ²⁺ uptake. <i>Life Sciences</i> , 1999, 66, 425-431.	2.0	16
1224	Supersensitive platelet glutamate receptors as a possible peripheral marker in schizophrenia. <i>International Clinical Psychopharmacology</i> , 1999, 14, 119-112.	0.9	30

#	ARTICLE	IF	CITATIONS
1225	Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. <i>International Clinical Psychopharmacology</i> , 1999, 14, 339-343.	0.9	139
1226	A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. <i>International Clinical Psychopharmacology</i> , 1999, 14, 177-180.	0.9	21
1227	A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder. <i>International Clinical Psychopharmacology</i> , 1999, 14, 177-180.	0.9	23
1228	Auto-amputation of the tongue associated with flupenthixol induced extrapyramidal symptoms. <i>International Clinical Psychopharmacology</i> , 1999, 14, 129-131.	0.9	15
1229	A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. <i>International Clinical Psychopharmacology</i> , 1999, 14, 177-80.	0.9	26
1230	A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1998, 105, 1082-1090.	1.1	116
1231	A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. , 1998, 13, 17-20.		17
1232	Behavioural changes in dogs with acral lick dermatitis during a 2 month extension phase of fluoxetine treatment. , 1998, 13, 435-437.		2
1233	Fluoxetine treatment of acral lick dermatitis in dogs: A placebo-controlled randomized double blind trial. <i>Depression and Anxiety</i> , 1998, 8, 21-23.	2.0	50
1234	Selective Serotonin Reuptake Inhibitor???Induced Disturbances of Haemostasis. <i>CNS Drugs</i> , 1998, 10, 441-446.	2.7	7
1235	Clozapine Associated Neutropenia and Cytomegalovirus Colitis. <i>Pharmacopsychiatry</i> , 1998, 31, 236-237.	1.7	11
1236	The platelet intracellular calcium response to serotonin in subsyndromal depression. <i>International Clinical Psychopharmacology</i> , 1998, 13, 107-110.	0.9	11
1237	Anesthetic Induction for ECT with Etomidate Is Associated with Longer Seizure Duration Than Thiopentone. <i>Journal of ECT</i> , 1998, 14, 89-93.	0.3	36
1238	Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. <i>Clinical Neuropharmacology</i> , 1998, 21, 176-80.	0.2	157
1239	Fluoxetine treatment of acral lick dermatitis in dogs: A placebo-controlled randomized double blind trial. <i>Depression and Anxiety</i> , 1998, 8, 21-23.	2.0	1
1240	A Neuropsychological Study of Prefrontal Lobe Function in the Positive and Negative Subtypes of Schizophrenia. <i>Journal of Genetic Psychology</i> , 1997, 158, 487-494.	0.6	26
1241	Mice lacking the <i>SKI</i> proto-oncogene have defects in neurulation, craniofacial patterning, and skeletal muscle development. <i>Genes and Development</i> , 1997, 11, 2029-2039.	2.7	174
1242	Citalopram-associated clitoral priapism. <i>International Clinical Psychopharmacology</i> , 1997, 12, 121.	0.9	35

#	ARTICLE	IF	CITATIONS
1243	An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. <i>International Clinical Psychopharmacology</i> , 1997, 12, 137-140.	0.9	49
1244	Acute phase proteins in major depression. <i>Journal of Psychosomatic Research</i> , 1997, 43, 529-534.	1.2	197
1245	P.2.009 A prospective randomised double blind controlled study of the efficacy of Lorazepam versus clothiapine in the control of acutely behaviorally disturbed patients. <i>European Neuropsychopharmacology</i> , 1997, 7, S197.	0.3	1
1246	A randomized controlled single blind study of the efficacy of clonazepam and lithium in the treatment of acute mania. , 1997, 12, 325-328.		19
1247	The augmented platelet intracellular calcium response to serotonin in anorexia nervosa but not bulimia may be due to subsyndromal depression. , 1997, 22, 57-63.		14
1248	Response of obsessive compulsive disorder to carbamazepine in two patients with comorbid epilepsy. <i>Annals of Clinical Psychiatry</i> , 1997, 9, 171-3.	0.6	6
1249	Antidepressant induced mania in obsessive compulsive disorder. <i>European Neuropsychopharmacology</i> , 1996, 6, 9-11.	0.3	15
1250	Lithium Blocks 45Ca^{2+} Uptake into Platelets in Bipolar Affective Disorder and Controls. <i>Clinical Neuropharmacology</i> , 1996, 19, 48-51.	0.2	16
1251	Serotonergic syndrome after concomitant use of moclobemide and fluoxetine. , 1996, 11, 146-147.		6
1252	Season of Birth and Schizophrenia: Southern Hemisphere Data. <i>Australian and New Zealand Journal of Psychiatry</i> , 1996, 30, 220-222.	1.3	15
1253	Superiority of Lithium Over Verapamil in Mania. <i>Journal of Clinical Psychiatry</i> , 1996, 57, 543-546.	1.1	46
1254	Lyme disease in South Africa. <i>South African Medical Journal</i> , 1996, 86, 741-4.	0.2	6
1255	Paroxetine induced withdrawal effects. <i>Human Psychopharmacology</i> , 1995, 10, 147-148.	0.7	15
1256	The platelet intracellular calcium response to serotonin is augmented in bipolar manic and depressed patients. <i>Human Psychopharmacology</i> , 1995, 10, 189-193.	0.7	41
1257	Enhanced blockade of 45Ca^{2+} uptake into platelets in manic patients with bipolar affective disorder with flunarazine and verapamil. <i>Human Psychopharmacology</i> , 1995, 10, 299-303.	0.7	1
1258	Spectral indices of cardiovascular adaptations to short-term simulated microgravity exposure. <i>Integrative Psychological and Behavioral Science</i> , 1995, 30, 201-214.	0.3	6
1259	Quality of Life, Sexual Functioning and Sex Role Identity After Surgical Orchidectomy in Patients with Prostatic Cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 1995, 29, 497-500.	1.4	26
1260	Moclobemide Twice Daily in the Treatment of Major Depressive Episode. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 4S-9S.	0.7	18

#	ARTICLE	IF	CITATIONS
1261	Fluoxetine and hemostatic function: a pilot study. <i>Journal of Clinical Psychiatry</i> , 1995, 56, 14-6.	1.1	134
1262	Dopamine increases platelet intracellular calcium in bipolar affective disorder and controls. <i>International Clinical Psychopharmacology</i> , 1994, 9, 291-294.	0.9	24
1263	Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. <i>Journal of the American College of Cardiology</i> , 1993, 22, A113-A118.	1.2	31
1264	Indications for computed tomographic brain scanning in psychiatric inpatients. <i>South African Medical Journal</i> , 1992, 82, 338-40.	0.2	9
1265	Effect of abrupt mitral regurgitation after balloon valvuloplasty on myocardial load and performance. <i>Journal of the American College of Cardiology</i> , 1991, 17, 872-878.	1.2	5
1266	Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease.. <i>Circulation</i> , 1991, 84, 1087-1099.	1.6	629
1267	Effect of mitral regurgitation and volume loading on pressure half-time before and after balloon valvotomy in mitral stenosis. <i>American Journal of Cardiology</i> , 1991, 67, 162-168.	0.7	15
1268	Alloxan-induced diabetes mellitus in the pregnant ewe: Metabolic and cardiovascular effects on the mother and her fetus. <i>American Journal of Obstetrics and Gynecology</i> , 1989, 160, 1239-1244.	0.7	15
1269	Impact of Pregnancy on Complications of Insulin-Dependent Diabetes Mellitus. <i>American Journal of Perinatology</i> , 1988, 5, 359-367.	0.6	9
1270	The So-Called Solid Hemangioblastomas of the Cerebellum and Vertebral Angiography. <i>Journal of Neurosurgery</i> , 1965, 22, 35-39.	0.9	3
1271	LEFT VENTRICULAR ANEURYSM IN A BANTU CHILD. <i>Heart</i> , 1964, 26, 859-861.	1.2	14
1272	CARCINOMATOUS INVOLVEMENT OF THE PERICARDIUM PRODUCING THE SYNDROME OF CONSTRICTIVE PERICARDITIS: REPORT OF A CASE. <i>Annals of Internal Medicine</i> , 1956, 45, 298.	2.0	4
1273	Intra-Abdominal Egg-Shell Calcifications Due to Silicosis. <i>Radiology</i> , 1956, 67, 527-530.	3.6	9
1274	SILICA PREGRANULOMA. <i>Archives of Dermatology</i> , 1955, 71, 645.	1.7	11
1275	Chronic Idiopathic Hypertrophic Osteoarthropathy. <i>New England Journal of Medicine</i> , 1952, 247, 123-126.	13.9	14
1276	Management commentary. , 0, , 237-239.		0
1277	Preventive strategies in bipolar disorders: identifying targets for early intervention. , 0, , 223-240.		1
1278	Diretrizes da World Federation of Societies of Biological Psychiatry (WFSBP) para tratamento farmacológico de transtornos depressivos unipolares, 1ª parte: tratamento agudo e de continuuação do transtorno depressivo maior. <i>Revista De Psiquiatria Clinica</i> , 0, 36, 17-57.	0.6	2

#	ARTICLE	IF	CITATIONS
1279	Adjunctive antioxidants for bipolar disorder. The Cochrane Library, 0, , .	1.5	0
1280	Management commentary. , 0, , 219-225.		1
1281	Pharmacological Treatment in the Early Phase of Bipolar Disorders: What Stage are we at?. , 0, .		5
1282	A Clinical Monitoring System for Clozapine. , 0, .		3
1283	Recent developments in the treatment of bipolar disorders. , 0, .		2
1284	Psychotherapies for the Psychoses. , 0, , .		3
1285	Diretrizes da World Federation of Societies of Biological Psychiatry (WFSBP) para tratamento biolÃ³gico de transtornos depressivos unipolares, 2Ãª parte: tratamento de manutenÃ§Ã£o do transtorno depressivo maior e tratamento dos transtornos depressivos crÃ4nicos e das depressÃµes subliminares. Revista De Psiquiatria Clinica. 0. 36. 58-76.	0.6	0